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ABSTRACT 
 
While dogma states that animals use L-amino acids, several D-amino acids have been found 
in animals including humans since the 1980s. Two D-amino acids have attracted significant 
research interests because of their cell-cell signaling functions in animal nervous systems. D-
serine (D-Ser) can affect the activity and plasticity of N-methyl-D-aspartate (NMDA) receptor, 
a molecule that forms the basis of learning and memory in the brain. D-aspartate (D-Asp) is 
found in neuroendocrine and endocrine tissues, potentially playing roles in hormone synthesis 
and/or release. However, many details on the physiological functions of D-Ser and D-Asp and 
their signaling pathways remain unknown. Extensive studies are needed to fully understand 
the roles of these two putative neuronal signaling molecules and their effects on the animal 
brain and endocrine functions.     
 
D-Ser and D-Asp biosynthetic enzymes are essential to study the physiological functions of 
the D-amino acids in animal nervous systems. However, the knowledge of such enzymes has 
been limited, especially the characterization of D-Asp synthetic enzymes. Although the first 
enzyme that can make D-Ser from L-Ser was isolated from animal brain tissue in 1999, the 
first nervous system associated D-Asp synthetic enzyme was not described until 2010. The 
lack of the knowledge of a D-Asp biosynthetic enzyme has significantly hindered the research 
of D-Asp physiological function in animal nervous system. The molecular mechanism 
underlying D-Asp action is still not clear. In invertebrates, high levels of D-Asp had been 
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found in central nervous systems (CNS) of some marine mollusks including Aplysia 
californica, a model animal for cellular and systemic neuroscience study, and D-Asp showed 
neurotransmitter behaviors in Aplysia CNS, indicating D-Asp signaling pathway is conserved 
among animal kingdoms. Thus, studying D-Asp in Aplysia can provide valuable insights into 
mammalian system function.  
 
As the biosynthetic pathway of D-Asp in invertebrate is not known, one significant goal of 
this project has been to uncover the biosynthetic enzyme responsible for the biosynthesis of 
D-Asp in cerebral ganglion in Aplysia CNS.  Using combining bioinformatics, molecular 
biology and biochemical methods, a d-amino acid racemase 1 (DAR1) has been discovered, 
cloned and characterized from the Aplysia CNS. The biosynthesis of D-Ser and D-Asp in 
Aplysia CNS cerebral ganglion F/C neuronal clusters via this enzyme has been characterized; 
these are the regions where high levels of D-Asp were previously detected. DAR1 is the first 
serine racemase and the first nervous system associated aspartate racemase described from an 
invertebrate system, and it is also the first enzyme with a dual serine and aspartate activity 
described in a eukaryotic system. The enzyme thus becomes a valuable model to  study D-Ser 
and D-Asp physiological functions in a well-characterized model system, to investigate D-Ser 
and D-Asp signaling pathways and their interactions, and to examine the structure-function 
relationships of pyridoxal-5’-phosphate (PLP) dependent amino acid racemase. 
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CHAPTER I 
INTRODUCTION 
 
1.1 D-amino Acid 
It is known that every amino acid, with an exception of glycine, has two chiral isoforms, L-
form and D-form, around alpha carbon chiral center. The enantiomers can convert among 
each other under extreme temperature or pH spontaneously, by chemical racemization during 
food processing (1) or by enzymatic racemization (2). For reasons still not clear to scientists, 
L-amino acids dominate in nature as building blocks of proteins and free molecules with 
various functions in organisms. D-amino acids, however, are widespread in bacteria where 
they can be found in bacterial cell walls in the form of peptidoglycan and antibiotics (3), and 
can regulate cell wall remodeling and cause biofilm dispersal as discovered recently (4). 
Contrary to the long-standing belief that D-amino acids are not present in higher organisms, 
free D-amino acids have been found during recent years in yeast, plants and animals including 
mammalian brains and endocrine tissues as endogenous molecules and play important 
physiological functions (5). The breakthrough of D-amino acid study in higher organisms 
came in 1990s when a series of study revealed that D-serine (D-Ser) was an endogenous 
molecule in rat brain as a co-agonist of N-methyl-D-aspartate  receptor  (6-8). Since then, D-
amino acid in eukaryotic systems has become a new discipline of study both in basic research 
and application sciences with an increasingly growing pace. A few topics of D-amino acid 
study are related to the major topics of this work involving amino acid racemase and thus are 
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reviewed in the next few passages. These topics include D-Ser, D-aspartate (D-Asp), 
invertebrate D-amino acid study with Aplysia and D-Ser and D-Asp biosynthetic racemases.  
 
1.2 D-Serine 
D-serine was first found at a significant quantity in rat brain and serum using HPLC method 
in early 1990s (9), later found in rat forebrain and concentrated in hippocampal dentate gyrus 
astrocytes, and shown to bind to the glycine binding site of N-methyl-D-aspartate receptor 
(NMDAR) (7). Subsequent studies proved that D-Ser was an endogenous molecule made 
from L-Ser via serine racemase (SR) in astrocytes (8) and that it modulates NMDAR activity 
(6).  It is now known that D-Ser is mainly made in neurons (10) and can be released from 
brain neurons (11), astrocytes (12, 13) and retinal glial cells (14).  D-Ser can be uptaken by 
glial cells and neurons by alanine-serine-cysteine transporter 1 (ASCT1) and ASCT2 (15, 16). 
D-Ser appears to be shuttled between neurons and glial cells to serve its neuromodulator 
function in neurons but uptake and stored in glial (10). D-amino acid oxidase (DAAO) plays a 
major role in biodegradation of D-Ser (17). D-Ser is now accepted as a novel small molecule 
neurotransmitter/neuromodulator. NMDAR activation requires both glutamate agonist bound 
to its NR2 subunit and co-agonist D-Ser bound to its NR1 subunit (10). The NMDAR is the 
basis of learning and memory, affecting brain development and plasticity (18), thus abnormal 
D-Ser metabolism can affect brain functions. It has been documented that an increased level 
of D-Ser and a decreased level of D-Ser in brain have been linked to neurodegenerative 
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diseases amyotrophic lateral sclerosis (19) and schizophrenia (20, 21), respectively. Therefore, 
the study of D-Ser is not only important to understand NMDAR functions but also important 
for searching for therapeutic targets for neural disorders.    
 
1.3 D-aspartate 
D-aspartate is another well studied D-amino acid in animals. The amino acid has shown some 
signaling functions in hormone regulations.  However, many details about D-Asp are not clear 
and the molecule remains enigmatic.  
 
D-Asp was first detected in plants and animals using D-aspartate oxidase (DAO) and HPLC 
in 1960s (22). Since then, D-Asp has been reported in almost every animal phyla (23) and in 
various tissues including brain (24, 25), retina (26), kidney and liver (27), endocrine tissues 
such as pineal gland and pituitary (28-30), adrenal gland (31, 32) and testis (33), and exocrine 
tissues (34, 35). D-Asp showed a peculiar temporal pattern during embryo development. It 
occurred at high levels in embryonic brain and retina of mammals and birds but quickly 
dropped to trace levels after birth (36, 37). In rat brain, D-Asp immunoreactivity was 
observed in distinct nerve cell population and its localization was almost the inverse of D-
aspartate oxidase (DAO) (31), suggesting the DAO involves the regulation of D-Asp content.   
 
The physiological roles of D-Asp in hormone synthesis and/or release in various endocrine 
tissues have been well documented. D-Asp can suppress melatonin release from pineal gland 
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(38), but it can stimulate prolactin and luteinizing hormone secretion from anterior pituitary 
(39, 40), and testosterone from testes (41) but inhibit oxytocin from posterior pituitary  (42). 
Studies also found that D-Asp plays some roles in hippocampal neurogenesis (43) and the 
maturation of adrenal gland (32). However, the molecular mechanism(s) underlying D-Asp 
physiological function remains unclear. Studies have produced a complex profile for D-Asp. 
A pharmacology study demonstrated the binding of D-Asp to NMDA-type receptor in rat 
Harderian gland with a lower affinity than L-glutamate (44). D-Asp seems to have some 
neuromoduatory effect on NMDAR because an abnormally high level of D-Asp strongly 
enhanced NMDAR dependent LTP in hippocampal area in a DAO knockout animal model 
(45). However, a study showed that D-Asp could potentiate L-Glu effects significantly on 
horizontal cells in goldfish retina (46); another study indicated that D-Asp improved hormone 
synthesis through cGMP secondary messenger (39). It looked like that D-Asp has more than 
one function by acting on different receptors, triggering different signaling pathways.   
 
Experiments on intracellular localization of D-Asp with immunohistochemistry (IHC) 
methods showed conflicting results. D-Asp was found predominantly associated with 
heterochromatin but undetectable in the other subcelluar structures in mammalian 
hypothalamo-neurohypohyseal system (47) suggesting a gene expression function; but it was 
located in PC12 (adrenal tumor cell line) and GH3 (pituitary tumor cell line) cytoplasm (48). 
The discrepancy of the IHC results could be due to staining techniques, antibody quality or 
different cell types.  
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 Evidences of release and uptake of D-Asp have also been accumulated. It has been shown that 
D-Asp was released from tissues containing significant levels of D-Asp or loaded with a high 
concentration of D-Asp to extracellular milieu. For example, D-Asp could be released from 
adrenal slices by the depolarization of KCl or acetylcholine stimulation (49), from Aplysia 
californica cerebral ganglia upon the stimulation of KCl or ionomycin (50), and from  
hippocampal nerve endings (51).   
 
The uptake of D-Asp experiments have shown that it could be uptaken by cultured rat 
pinealocytes (38, 49), astrocytes through an excitatory amino acid transporter (EAAT) (52), 
PC12 cell through a glutamate transporter-mediated pathway (53) and Aplysia cerebral 
ganglion (50).  
 
The biosynthetic pathway of D-Asp in an animal nervous system was not known until very 
recently when the first mammalian Asp racemase (DR) was reported in 2010 (43) and the first 
invertebrate DR was published by us this year (47). The two DRs are distinct enzymes with 
different catalytic mechanisms. It is clear that there is more than one biosynthesis pathways 
are involved but how many remains to be answered.   
 
Accumulated evidences so far have depicted D-Asp as a signaling molecule with some 
features of a classical neurotransmitter like D-Ser.  But extensive studies are needed to fully 
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understand the mechanisms of D-Asp physiological functions in nervous system and/or 
endocrine systems.   
 
1.4 D-amino Acid study with Aplysia californica  
Research evidences with invertebrates have indicated that D-Ser and D-Asp signaling 
pathways are likely conserved among animal kingdoms. D-Ser has been found in Aplysia 
californica CNS (54, 55) and D-Asp found in a variety of tissues in ocean invertebrates CNS 
(23, 24, 56, 57), endocrine tissues (33, 58) and visual systems (26). Studies with Aplysia on 
D-Asp have pointed a profile of a neurotransmitter. Thus D-amino acid study with Aplysia 
can shine some lights on the function of the amino acid in mammalian systems.   
 
Aplysia californica is a marine mollusk animal model for cellular and systemic neuroscience 
study. Aplysia CNS has many giant and identifiable neurons thus it is a suitable model to 
study single neuron profiling and neural network. Using analytical instrumentation capillary 
electrophoresis laser induced fluorescence detection (CE-LIF), D-Asp was first detected in 
Aplysia neuronal clusters and single neurons (59). D-Asp content, expressed as percentage of 
D-Asp in total Asp, was found distributed unevenly among cerebral ganglion neuronal 
clusters with the highest content found in F clusters (80 %) and lowest found in neighboring 
A clusters (40%), suggesting the endogenous origination of D-Asp and a possible 
physiological function in Aplysia CNS (24). The amino acid could stimulate the release of 
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cardiomodulatory peptide from R3-14 neurons (60), be released from cerebral ganglia in a 
stimulation dependent manner and uptaken by cerebral ganglion F-clusters, and might be 
synthesized by a PLP-dependent aspartate racemase activity in cerebral ganglion using 
radionuclide pulse-and-chase (50). To define D-Asp biological nature in Aplysia CNS, it was 
essential to describe the enzyme that makes D-Asp in vivo.   
 
1.5 Significance of D-serine and D-aspartate Biosynthetic Enzymes 
The knowledge of biosynthetic pathways of a D-amino acid in a nervous system is essential to 
define whether a molecule is a neurotransmitter, and a D-amino acid synthetic enzyme is a 
powerful tool to study the functions of a D-amino acid and its signaling pathway. The 
discovery of SR and co-localization of SR with D-Ser in rat astrocytes and neurons provided 
the ultimate proof that D-Ser was made in brain tissues in 1999 and quickly established the 
physiological function of D-Ser in animal brain (8).  However, a decade-delayed discovery of 
DR in animal nervous system has significantly hindered the research of D-Asp in animal brain 
functions. Recent cloning of the first mouse DR has helped to discover D-Asp role in 
hippocampal neurogenesis (43). However, the knowledge of animal DR in nervous system 
has just started to emerge. Studies with invertebrate system can provide insights into 
vertebrate systems including human system. Racemase study is the theme of my dissertation 
research, thus I have dedicated Chapter II to review amino acid racemases extensively.   
 
1.6 Goal and Significance of Research Project  
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My research project was to find a novel enzyme that is responsible for D-Asp biosynthesis in 
Aplysia CNS cerebral ganglion where exceptionally high levels of D-Asp was previously 
detected in some isolated neuronal clusters by CE-LIF and where D-Asp behaved like a 
neurotransmitter. But the biosynthetic enzyme for the D-Asp in Aplysia CNS was not known. 
The discovery of the enzyme provides an evidence for defining the D-Asp as a 
neurotransmitter/neuromodulator in Aplysia. The enzyme would establish Aplysia as the first 
model to study D-amino acid signaling pathway in an invertebrate system. The enzyme can 
also be used to study the structure and function relationship of eukaryotic racemases and shine 
some lights on racemase evolution.  
  
1.7 Summary of Research Methods and Dissertation Chapters 
A battery of modern biological techniques was used to accomplish Aplysia d-amino acid 
racemase 1 (DAR1) project. Bioinformatics tools were used for searching racemase gene from 
Aplysia genome database and analyzing various protein properties based on its primary 
sequence. A variety of molecular biology techniques have been used to clone the complete 
cDNA sequence of Aplysia genes, and to construct protein expression vectors. Protein 
chemistry techniques were used to express and purify proteins from microbial expression 
systems, and to measure protein quantity and quality. Biochemical enzyme assay, both 
qualitative and quantitative, were used to describe enzyme characteristics and measure 
kinetics. Immunology techniques were used to make polyclonal and monoclonal antibodies, 
and to perform Western blot and IHC to examine protein expression and localization in 
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Aplysia tissues. Finally, analytical chemistry method CE-LIF was used for analyzing 
racemase reaction results, which was essential for the success of the project.  
 
The contents of subsequent Chapters are summarized below. Chapter II is a detailed review of 
amino acid racemase that is the focus of my dissertation topics. Chapter III and Chapter IV 
cover my major Ph.D. research project on DAR1. In Chapter III, the discovery of DAR1, 
from gene to enzyme, was described in detail. The discovery has established Aplysia as the 
first invertebrate model to study D-Asp and D-Ser. The contents of this chapter have been 
published. In Chapter IV, the L-Ser β-eliminase activity of DAR1 was described by side-by-
side comparisons with Aplysia serine dehydratase AcSDH, a novel and distinct enzyme with 
the same β-eliminase activity. A new hypothesis was proposed on the basis of the study to 
explain the physiological function of DAR1 β-eliminase activity. The hypothesis, if 
confirmed by others, would provide a general answer to the β-elimination activity of 
eukaryotic serine racemase which has been under debate. The contents of Chapter IV are in 
the preparation for a journal article submission. Chapter V includes three methods that were 
used for DAR1 projects but not described in the previous chapters; it also includes the 
descriptions of two experiments, one of which is generating monoclonal antibody against D-
amino acid containing peptide (DAACP), and the other is suprachiasmatic nucleus (SCN) 
microdialysis fluid analysis for L-glutamate neurotransmitter change using CE-LIF method. 
The two experiments are not directly associated to the DAR1 project but they are parts of D-
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amino acid study and neurotransmitter study which are under the same theme of my 
dissertation research.     
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CHAPTER II 
AMINO ACID RACEMASES 
 
2.1 Introduction 
Free D-amino acids are essential for bacterial growth as cell wall peptidoglycan components, 
and they are also present in archaea with putative function related to the uptake of D-amino 
acids formed under high temperature stress (1). Oddly, the four D-amino acids (D-Ala, D-Ser, 
D-Asp and D-Glu) found in bacterial cell wall peptidoglycan materials have been discovered 
as endogenous molecules in various eukaryotic organisms including mammals during recent 
years and have shown a range of important physiological functions (2-4). In animals, D-Ser is 
a neurotransmitter/neutromodulator acting on NMDA receptor in CNS (5), D-Asp plays roles 
in hormone synthesis/release in CNS and peripheral endocrine tissues (6) and D-Ala is 
implicated affecting insulin secretion from pancreas (7). D-Glu occurs in animal CNS in 
significant amount but its function has not been revealed (8, 9). It is obvious that D-amino 
acid studies in animals not only is important in basic science but likely has clinical 
significance.  
 
The knowledge of D-amino acid biosynthetic enzymes is essential to understand the 
physiological functions of D-amino acids and D-amino acid signaling pathways in animals. It 
is known that in bacteria D-amino acids for peptidoglycan syntheses are mainly made by 
amino acid racemases (1) which can catalyze interconversion between an L-amino acid and its 
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D-amino acid counterpart. Amino acid racemases are found not only in bacteria but also in 
archaea, fungi, yeast, plant and animals (2). There are two categories of amino acid racemase. 
One class requires pyridoxal-5’-phosphate (PLP, or a vitamin B6 active form) cofactor for 
activity, and are termed PLP-dependent racemases; another class is cofactor free, or termed 
PLP-independent racemase. PLP-independent racemases have mostly been found in bacterial 
and archaea, but PLP-dependent racemase occurs in prokaryotes, archaea and eukaryotes. 
Both classes of amino acid racemases are found in many bacteria phyla and have been well 
studied. The knowledge of bacterial D-amino acid biosynthetic pathways has helped to find 
eukaryotic racemase. So far, about total a dozen of eukaryotic amino acid racemases have 
been described from yeasts (10, 11), plants (12) and animals (13-15). However, the 
knowledge of racemase associated with animal brain and/or endocrine tissue is limited and 
growing slowly. Three serine racemases in mammalian brains were described by 2000, but the 
first aspartate racemase from an animal nervous system was described in 2010; and so far no 
alanine and glutamate racemases have been found in animal nervous/endocrine tissues 
although both D-Ala and D-Glu have been found in CNS in significant amounts. Therefore it 
is necessary and important to find new racemases from animal nervous systems and use them 
to study D-amino acids in animals. A recent approach to find a new enzyme is to search 
annotated target genes or search genomes for a target gene from scratch using known protein 
sequences or structures. Once a target gene is found, the gene can be cloned and expressed 
and its protein can be characterized. Therefore the knowledge of known enzymes is very 
important for discovering and characterizing new enzymes of similar functions. The goal of 
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this review is to gather information from the amino acid racemases studied so far by 
describing some representative racemases from bacterial, archaea, yeast, plants or animals. 
The information can facilitate D-amino acid racemase studies and aid in understand this 
elusive and intriguing modification in animals. 
  
2.2 Amino Acid Racemase Catalytic Mechanisms and Structures 
2.2.1 PLP-independent racemase 
Enzyme structure and catalytic functions are essential to understand an enzyme. As mentioned 
above, there are two classes of amino acid racemase: PLP-independent racemases and PLP-
dependent racemases. Their structures and catalysis mechanisms are distinct. However, the 
basis of amino acid racemization is the same. It involves the initial removal of α-proton from 
an amino acid substrate and then a reprotonation of the same substrate but on the opposite 
face of the resulting planar anionic intermediate. The tasks of α-proton abstraction and 
addition are performed by enzyme residues for PLP-independent enzymes or performed by 
enzyme residues but aided by PLP for PLP-dependent enzymes as shown in Figure 2.1. This 
section describes catalytic mechanism of PLP-independent enzymes using bacterial glutamate 
racemase as an example.   
Cofactor free amino acid racemase either uses one cysteine base to perform both α-proton 
abstraction and delivery task or use two cysteine bases with one abstraction base and one 
delivery base for α-proton transfer. The one-base mechanism is used by bacterial proline 
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racemase (16, 17), and two-base mechanism is used by bacterial glutamate racemase, bacterial 
aspartate racemases and archaea aspartate racemase (1), and proline racemase from human 
parasite Trypanosoma cruzi (18).  
  
Much knowledge of PLP-independent two-base catalysis mechanism came from the mutation 
studies of glutamate racemase (EC 5.1.1.3) from bacteria Pediococcus pentosaceus (19), and 
structural studies of glutamate racemase (MurI) from Aquifex pyrophilus (20) and 
Lactobacillus fermenti (21). Crystal structure analysis of MurI revealed that the enzyme forms 
a dimer and each monomer consists of two α/β fold domains, D-glutamine analog binds to the 
deep pocket formed by conserved residues from two monomers. Two-base catalytic 
mechanism by Lactobacillus fermenti glutamate racemase is shown in Figure 2.2. The 
racemization catalytic task is achieved by two active-site cysteine residues Cys73 and Cys184 
which act as catalytic bases: thiolate of one cysteine serves to deprotonate the substrate, and 
the thiol of the second cysteine protonates the carbanionic intermediate in the opposite face. 
The task is difficult because the pKa of the α-proton of the amino acid is about 21 (22) and 
that of a thiol is around 10; therefore, in order to act as catalytic bases to withdraw α-proton 
from the substrate, the thiols need to be assisted by other residues. Crystal studies showed that 
Asp10 and Hi186 assisted the functions of Cys73 and Cys184 through hydrogen bonds, 
respectively (1, 21).  
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2.2.2 PLP-dependent Racemase 
PLP-dependent enzymes catalyze a large variety of chemical reactions mainly involved in 
amino acid metabolisms. These enzymes have been divided into fold types on the basis of 
evolutionary relationships and protein structural organization (23).  Different fold-types share 
limited structural similarities even though they appear to  catalyze similar reactions; there is 
no correlation between fold-types and reaction specificities, for example, amino acid 
racemases have been found in fold-type I, II and III thus considered to be evolved from three 
divergent pathways (2). Bacterial alanine and serine racemases are PLP-dependent enzymes 
and all eukaryotic racemases found so far are also PLP-dependent enzymes, thus PLP-
dependent catalysis mechanism is more advanced than PLP-independent mechanism.    
 
Bacterial alanine racemase (EC 5.1.1.1) is wide present in bacterial kingdoms and it is an 
essential enzyme for bacteria growth for it makes D-Ala, an indispensible component of cell 
wall peptidoglycan. The enzyme is thus a drug target for antibiotics (23) and is the best 
studied fold-type III PLP-dependent amino acid racemase. The enzyme was first cloned and 
charaterized by Tanizawa et al. from Bacillus stearothermophilus (24). The structural studies 
with the B. stearothomophilus alanine racemase revealed a homodimeric enzyme with each 
monomer consisting of an α/β barrel domain at the N-terminus (residue 1-240) and a C-
terminal domain (241-388) composed mainly of β-strand as shown in Figure 2.4. In the 
structure of the dimer, the mouth of the alpha/beta barrel of one monomer faces the second 
domain of the other monomer. The PLP cofactor lies in and above the mouth of the alpha/beta 
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barrel (25). The enzyme uses two-base mechanism as shown in Figure 2.3. The task of α-
proton abstraction is carried out by Try265’ and Lys39 to remove α-proton from L- and D-
alanine, respectively. The hydrogen transfer between Try265’ and Lys39 was mediated by 
carboxylated oxygen atom of L-alanyl-PLP aldimin or D-alanyl-PLP aldimin. In this 
mechanism, the phenolic hydroxyl group of Try265’ removes α-proton from L-alanyl-PLP 
adlimin and donates it to the carboxylate group of the aldimin, the resulting carboxylate group 
then donates the proton to the ε-amino group of Lys39 which in turn donates it to Cα to form 
the D-alanyl-PLP aldimine. PLP directly interact with alanine to form Schiff base and become 
quinonoid intermediate after α-proton was removed and it not only forms the intermediate but 
stabilizing it (1). The similar mechanism is used by bacterial serine racemase VanT from 
Enterrococcus gllinarium where PLP-binding Lys371 and Try597 remove α-hydrogen from 
L-Ser and D-Ser, respectively (26).  
 
Eukaryotic serine racemase (EC 5.1.1.18) was first isolated from rat by Wolosker et al. (27). 
It is the best studied eukaryotic racemase and human serine racemase is now a potential drug 
target for schizophrenia (28). The enzyme has a different structure from alanine racemase and 
it is belongs to fold-type II PLP-dependent enzyme as shown in Figure 2.4. The crystal 
structures of fission yeast, human and rat serine racemases have been described (11, 29). The 
structures have revealed a typical fold-type II PLP-dependent enzyme family with both a large 
domain and a flexible small domain associated into a symmetric dimer, and indicated a 
ligand-induced rearrangement of the small domain that organizes the active site for specific 
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turnover of the substrate (11, 29). PLP-binding Lys57 (yeast), and PLP-stabilizing residues, 
Asn84 (yeast), Glu281 (yeast) and Asn311 (yeast) are conserved in all eukaryotic SR 
discovered so far (11). Eukaryotic serine racemase is structurally similar to E. coli. 
biosynthetic L-threonine dehydratase (EC 4.2.1.16). The N-terminal domain (1-320) of the E. 
coli enzyme contains a PLP attachment motif and the domain shares 31% sequence identity 
with mouse serine racemase of 334 amino acids.  
 
Another type of PLP-dependent amino acid racemase is represented by mouse aspartate 
racemase (30). The enzyme is distinct from alanine racemase (prokaryotes or eukaryotes) and 
serine racemase (eukaryotes) both in catalytic mechanisms and the structure. It is conserved 
with aspartate aminotransaminase (2.6.1.1). There is no structural information on the enzyme 
but it is likely belongs to fold-type I PLP-dependent enzyme (2).     
 
2.3 Bacterial and Archaea Racemases 
D-Ala is an essential cell wall component across bacterial kingdom and alanine racemase is 
widespread in bacteria. Two distinct alanine racemase genes have been cloned from 
Salmonella typhimurium termed dadB and alr, but only alr enzyme plays role in 
peptidoglycan assembly, both enzymes are PLP-dependent and share large homology (31). 
Some bacteria have homolog of both genes but others have homolog of one gene (1).  
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D-Glu is strictly conserved across bacterial kingdom occurring in peptidoglycan second 
residue incorporated. The amino acid is vital for bacterial growth and is mostly synthesized by 
cofactor free and two-thiol-based glutamate racemase; the conserved and essential feature of 
glutamate racemase across bacterial kingdom makes it a drug target for anti bacterial agents 
(32).  
 
D-Asp also occurs in the peptidoglycan of some bacterial strains. Aspartate racemase (EC 
5.1.1.13) has been demonstrated in various Lactobacillus and Streptococcus strains (33). Like 
bacterial glutamate racemase, bacterial aspartate racemase is also PLP-independent enzyme 
using cysteines as catalytic bases (1). But the enzyme is less spread among bacteria than 
glutamate racemase.  
 
Bacterial serine racemase only occurs in some strains. It is PLP-dependent enzyme and shares 
conserved PLP-binding Lys and Try residues with alanine racemase at its C-terminus. The 
enzyme plays an important role in vancomycin resistance by modifying peptidoglycan 
precursor from D-Ala-D-Ala to D-Ala-D-Ser (34, Arias, 1999 #17). The enzyme shares little 
similarity to eukaryotic serine racemase.  
 
Archaea contains significant free D-enantiomers of serine, alanine, proline, glutamate and 
aspartate (35) but the physiological functions of the D-amino acids are not clear. PLP-
independent archaea aspartate racemase have been isolated from archaea Desulfurococcus and 
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Thermococcus (33, 36). Desulfurococcus enzyme shares high homology with bacterial 
glutamate racemase around putative cysteine catalytic sites. The enzyme might serve a 
function of uptake of Asp formed under high temperature or producing D-Asp for cell 
component (33, 36). Crystal structure analysis with mutants and molecular dynamics 
simulations revealed that archaea DR also use two cysteines as catalytic bases (37, 38).  
 
It is worth describing several details related to the archaea serine racemase from Pyrobaculum 
islandicum (39). The enzyme has an increased activity between 20 °C and 100 °C. Archaea 
serine racemase is a PLP-dependent enzyme and shares 30% sequence identity to mouse 
serine racemase (will be described below), and 34% and 29% identity to E coli threonine 
dehydratase catabolic and biosynthetic enzyme, respectively. It also contains a conserved 
motif of SFKIRG among serine/threonine dehydratase from human, rat, yeast and E. coli and 
share 66% homology to other archaea threonine dehydratase in primary sequence. The 
archaea enzyme is similar to both eukaryotic serine racemase and serine/threonine 
dehydratase in enzyme characters. The enzyme has broad racemase substrate specificities 
towards L-Ser, L-Thr, D-Ser and D-Thr while mammalian serine racemases have no threonine 
racemase activity. Both archaea and mammalian serine racemases have dehydratase activity 
towards L-Ser and L-Thr and their dehydratase activities are much stronger than their 
racemase activities. However, mammalian serine racemase is activated by ATP-Mg2+ but 
archaea serine racemase is inhibited by ATP and activated by AMT and no response to Mg2+ 
and Ca2+. The response to ATP and Mg2+ is similar to serine/threonine dehydratase from 
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Aplysia (see Chapter IV for AcSDH data).  The physiological function of the archaea enzyme 
is not clear but it is not involved in ATP or isoleucine production (39). From the phylogenetic 
tree as shown in Figure 2.6, it appears that archaea serine racemase is closer to E. coli 
threonine dehydratase than eukaryotic serine racemase clusters and it could be a distant 
ancestor of eukaryotic serine/aspartate racemases. It is interesting that Aplysia racemase 
DAR1 (will be described below) is heat stable even above 50 °C, a possible trace feature of an 
ancestor enzyme living under high temperature.  
 
2.4 Eukaryotic Racemase   
2.4.1. Serine Racemase 
Serine racemase is responsible for D-Ser biosynthesis in mammalian brains (40). Because D-
Ser is a co-agonist to NMDA receptor, the aberrant metabolism of D-Ser can affect the 
function of the key receptor for learning and memory as accumulated evidences have indicted 
(41). The important physiological function of D-Ser has made serine racemase the most 
studied eukaryotic amino acid racemase in animals. Human serine racemase is a target for 
drug development for neurodegenerative disorders such as schizophrenia and ALS (42).   
 
Eukaryotic serine racemases have been cloned and characterized from 7 organisms including 
fission yeast S. pombe (43), plant A. thaliana and H. vulgare (12, 44), mollusk A. californica 
(15), and human, rat and mouse (13, 27, 45). Putative SR genes are widespread in animal 
genomes. The enzymes are highly conserved and contain 323-340 amino acid residues and 
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share more than 37 % protein sequence identity to each other with a conserved PLP-binding 
motif at N-terminus around PLP-interacting Lys57 (yeast) and PLP-stabilizing residues, 
Asn84 (yeast), Glu281 (yeast) and Asn311 (yeast) as shown in Figure 2.5 multiple sequence 
alignment in Fig. 2.5. Human SR gene contains seven exons and localizes to chromosome 
17q13.3 (13); Aplysia dar1 gene discovered by us is composed of 26,276 nucleotides and 
contains 9 exons. Rat and mouse SR have a serine deletion compared to human homolog; and 
rat SR seems to have a nonsense mutation that occurred at 334th codon thus terminated earlier 
than mouse and human SR, leading to a 6 amino acid truncation at C-terminus (46).  
 
The crystal structures of human, rat and fission yeast serine racemases have been described. 
The structures revealed a typical fold-type II of PLP-dependent enzyme family (11, 29). The 
enzymes catalyze interconversion between L-Ser and D-Ser with smaller Km to L-Ser 
substrate but larger Vmax towards D-Ser. Aplysia DAR1 also has significant aspartate racemase 
activity (15). The racemization kinetics parameters, especially Vmax vary significantly from 
one enzyme to the other, with about as much as 90 folds difference. For example, for L-Ser 
racemase reactions, the Vmax of A. thaliana SR and A. californica DAR1 are 2.0 nmol/mg/min 
and 11 µmol/mg/h respectively (15, 44). The difference might be due to the different assay 
conditions and/or product detection methods used to measure the kinetics. With no exception, 
however, all serine enzymes also have β-eliminase activity capable of degrading L-Ser, or L-
Thr and D-Ser in some cases, to α-keto acids and ammonia. L-Ser β-eliminase activity is 
usually 2-4 folds stronger than serine racemase activity (44, 47). Both racemase and 
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dehydratase activities favor alkaline conditions with racemase activity more so than 
dehydratase activity (15, 48). The enzymes, except for plant SR, are activated by ATP-Mg2+ 
allosteric effectors. However, ATP was not hydrolyzed during human SR activation (49). The 
physiological function of mammalian SR racemase is to make NMDAR co-agonist D-Ser, but 
β-elimination activity of serine racemases is under debate which is discussed extensively in 
Chapter IV.  
 
The intercellular and intracelluar localizations of animal serine racemase have been observed. 
Rat serine racemase is located in both glial cells and neurons confirmed by 
immunohistochemistry staining technique and in the cytoplasm of cells (41). But whether the 
enzyme is in some subcellular vesicles is not known. Given the fact that animal serine 
racemase needs an alkaline condition to achieve a maximal catalytic rate, the enzyme might 
act in some basic subcellular compartments or by other mechanisms unknown. One possible 
mechanism is to raise pH surrounding enzyme catalytic pocket by ammonia produced by 
racemase β-elimination activity. Serine racemase also exists in peripheral tissues. Northern 
blot analysis found that human SR is expressed in brain, heart, skeletal muscle, kidney and 
liver tissues with at least three different sizes of mRNA transcripts present in heart and kidney; 
and the SR was also localized by Western blot in hippocampus, thalamus, and amygdala glial 
cells (50). In Aplysia, Western blot localized DAR1 in brain, liver and atrial gland as a single 
band of predicated size but a larger protein band was present in ovotestis besides a very faint 
band of the predicated size (15). Aplysia atrial gland is known to secret a family of peptides 
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that can stimulate egg laying (51), suggesting that DAR1 might play a role in the hormone 
synthesis/release in the atrial gland and possible through D-Asp made by DAR1 aspartate 
racemase activity.  
  
Mammalian serine racemase regulation has been studied.  Rat serine racemase is activated by 
glutamate transmission via glutamate interacting protein which binds to α-amino-3-hydroxy-
5-methyl-4-isoxazolepropionic acid (AMPA) receptor subtypes of glutamate receptor. The 
binding of the serine racemase to the glutamate receptor binding protein augmented enzyme 
activity which leads to the enhancement of neonatal cerebellum granule cell migration (52). 
Serine racemase activity is inhibited upon S-nitrosylation by neuronal nitric-oxide synthase, 
which might be one of the mechanisms modulating NMDA neurotransmission long term 
potentiation via nitric oxide (NO) in a retrograde manner (53).  
 
2.4.2 Aspartate Racemase 
D-Asp has shown physiological functions in hormone synthesis/release and neurogenesis. But 
the mechanisms underlying D-Asp function is not defined. Studies have depicted a complex 
picture of a signaling molecule. Aspartate racemase makes D-Asp in vivo (15, 30) but the 
knowledge of aspartate racemase in animal nervous systems just started to emerge. The first 
enzyme in an animal nervous system was not described until 2010. The scarce information on 
aspartate racemase from a nervous system and/or an endocrine system has hindered the study 
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of D-Asp function in those tissues. Extensive studies are needed to study described enzymes 
and discover new aspartate racemases from animal nervous and endocrine systems.   
 
So far, only three total aspartate racemases have been described from eukaryotes including 
two mollusk enzymes and one mouse enzyme. All three enzymes are PLP-dependent but 
represent two distinct enzyme families based on catalytic mechanisms. Mollusk S. 
broughtonii aspartate racemase (EC 5.1.1.13) from foot muscle and A. californica DAR1 (the 
enzyme also has serine racemase activity) from CNS are very close to each other sharing 55% 
sequence identity, and to serine racemase family sharing larger than 40% of sequence identity. 
Mouse serine racemase, however, belongs to aspartate aminotransferase (AST) family (EC 
2.6.1.1) with less than 15% sequence homology with Sb DR and DAR1. It is not known if Sb 
DR is present in bivalve brain but DAR1 and mouse DR occur in animal nervous systems. It 
is clear now that there are at least two different aspartate racemases that can make D-Asp 
from L-Asp in animal brains. Based on the structure and catalytic mechanisms, two aspartate 
racemases have evolved from two divergent pathways (see Figure 2.6 phylogenetic tree). 
How many enzymes involved in making D-Asp is unknown. But enzymes that make D-Asp in 
various animal tissues must be present. By careful analyzing known enzymes that can make 
D-Asp in bacteria, archaea and eukaryotes can provide clues to find new aspartate racemase 
from animal genomes. 
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There is no structural information on PLP-dependent aspartate racemase. However, based on 
sequence homology and highly conserved catalytic residues between serine racemase and 
mollusk aspartate racemases, it can be assumed that the marine animal aspartate racemases 
belong to fold-type II PLP-dependent enzymes. The mouse DR is likely a fold-type I PLP-
dependent enzyme because aspartate aminotransaminase is fold-type I enzyme (23). Both Sb 
DR and DAR1 have Asp racemase activity but DAR1 also has serine racemase activity that 
Sb DR is inactive on serine. Both enzymes display a smaller Km for L-Asp but larger Vmax for 
D-Asp substrate reactions, meaning L-Asp is likely a substrate in vivo; and like all serine 
racemase, both enzymes have L-Ser dehydratase activities (14, 15). However, Sb DR and 
DAR1 might have different physiological functions in vivo because Sb DR is inhibited by 
ATP in a non-competitive manner and promoted by AMP (54) while DAR1 is opposite (see 
Chapter IV data); Sb DR does not need Mg2+ to activate (55) but DAR1 is strongly activated 
by ATP-Mg2+ (15), indicating that the two enzymes play different physiological roles. It is 
known that Aplysia genome does not contain any other gene that is closer to Sb DR than dar1, 
suggesting that different aspartate racemase can have different function in different tissues in 
marine mollusks. Mouse DR plays some roles in hippocampal neurogenesis (30).  
 
2.4.3 Alanine Racemase 
Free D-alanine has been found in aquatic crustaceans and bivalve mollusks  (56), insect (57), 
plant seeds (58), mammalian brain anterior pituitary (7, 59) and pancreas (60). Research has 
30 
 
indicated that D-Ala is responsible for the intracellular isosmotic regulation in the tissues of 
crustaceans and bivalves under high salinity stress (56). Alanine has shown to colocalize with 
insulin secreting β-cells in pancreas (60) and correlate with circadian cycle with high levels 
during sleeping period and low levels during active period in rats with both diurnal and 
nocturnal habits (7). Alanine racemase have been cloned from prawn Marsupenaeus 
japonicus muscle and hepatopancreas (61), and from fission yeast (10). Protein sequence 
homology analysis concluded that eukaryotic and prokaryotic alanine racemases are 
conserved PLP-dependent enzymes and with similar catalytic residues (61). D-Ala 
physiological function in animals has not been defined. So far no alanine racemase has been 
isolated from vertebrates or from a nervous system where significant amount of D-Ala has 
been found. More studies are needed to find such enzymes to facilitate study of D-Ala in 
animals.   
 
2.4.4 Proline racemase 
Free D-proline (D-Pro) has been found in significant amounts in mouse anterior pituitary, 
posterior pituitary and pineal glands. In the peripheral tissues, the amounts of D-Pro were 
high in the pancreas and kidney, and at least some D-Pro is endogenously made (62), thus D-
Pro might have some biological functions in mammals. However, no proline racemase has 
been discovered from animal systems except from human parasite Trypanosoma cruzi (63). 
The T. cruzi proline racemase, however, is a PLP-independent amino acid racemase and is the 
only PLP-independent enzyme being found in eukaryotes so far.  In contrast to bacterial 
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proline racemase, which uses one cysteine base mechanism (17), the T. cruzi proline enzyme 
uses two-cysteine base catalytic mechanism (18). The parasite enzyme has received a 
significant amount of attention because it can trigger host B cell polyclonal activation, which 
prevents specific humoral immune responses, and is crucial for parasite evasion and 
persistence in the human host.  In addition, the enzyme is responsible for free D-proline 
biosynthesis. The function of free D-Pro is not known in the parasite but D-Pro is present in 
some peptides in non-infective epimastigote and infective metacyclic parasite forms. The D-
Pro-containing peptide might be beneficial for resistance to degradation by host protease (64).   
 
The study of D-Pro in animals is just beginning. The discovery of proline racemase will 
advance the study of D-Pro in the neuroendocrine tissues where significant amount and 
endogenous D-Pro has been found.   As of now, not only little is known about the racemase, 
the function of this D-amino acid remains enigmatic. 
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2.5 Figures 
 
 
 
 
 
 
 
Figure 2.1 Racemization of amino acid (A) and the role of PLP (B). Reproduced with permission from 
Yoshimura and Goto (2). 
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Figure 2.2 Catalytic mechanism of PLP-independent glutamate racemase from L. fermenti. 
Reprinted with permisson from Tanner et al.(65). 
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Figure 2.3 Catalytic mechanism PLP‐dependent alanine racemase from B. stearothermophilus. 
Reprinted with permission from Tanner et al. (65) .   
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Figure 2.4 Structures of two PLP‐dependent amino acid racemase. S. pombe serine racemase (fold‐
type II) (A) and G. stearothermophilus alanine racemase (fold‐type III) (B).  Figure reproduced with 
permission from Yoshimura and Goto (2). 
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Mouse_SR          -----------MCAQYCISFADVEKAHINIQDSIHLTPVLTSSILNQIAGRNLFFKCELF 
Rat_SR            -----------MCAQYCISFADVEKAHLNIQDSVHLTPVLTSSILNQIAGRNLFFKCELF 
Human_SR          -----------MCAQYCISFADVEKAHINIRDSIHLTPVLTSSILNQLTGRNLFFKCELF 
At_SR             --------MEANREKYAADILSIKEAHDRIKPYIHRTPVLTSESLNSISGRSLFFKCECL 
Hv_SR             MGSRDDDGHSTEGQGYAADINSIREARARIAPYVHKTPILSSTSIDAIAGKQLFFKCECF 
Aplysia_DAR1      -----------MAASCGVTFVDVLKALERISPFIHKTPIFTSEQANRKCGRQLFFKCENF 
yeast_SR          ----------MSDNLVLPTYDDVASASERIKKFANKTPVLTSSTVNKEFVAEVFFKCENF 
                                       .: .*  .*    : **:::*   :     .:***** : 
 
Mouse_SR          QKTGSFKIRGALNAIRGLIPDTPEEKPKAVVTHSSGNHGQALTYAAKLEGIPAYIVVPQT 
Rat_SR            QKTGSFKIRGALNAIRGLIPDTLEGKPKAVVTHSSGNHGQALTYAAKLEGIPAYIVVPQT 
Human_SR          QKTGSFKIRGALNAVRSLVPDALERKPKAVVTHSSGNHGQALTYAAKLEGIPAYIVVPQT 
At_SR             QKGGAFKFRGACNAVLSLD---AEQAAKGVVTHSSGNHAAALSLAAKIQGIPAYIVVPKG 
Hv_SR             QKAGAFKIRGASNSIFALD---DSQAAKGVVTHSSGNHAAAVALAAKLRGIPAYIVIPKN 
Aplysia_DAR1      QKSGSFKARGALNAVLKCQ--QVKPNVNGVVTHSSGNHGQALAWAAQRANLPCCVVVPQM 
yeast_SR          QKMGAFKFRGALNALSQLN---EAQRKAGVLTFSSGNHAQAIALSAKILGIPAKIIMPLD 
                  ** *:** *** *::             .*:*.*****. *:: :*:  .:*. :::*   
 
Mouse_SR          APNCKKLAIQAYGASIVYCDPSDESREKVTQRIMQETEGILVHPNQEPAVIAGQGTIALE 
Rat_SR            APNCKKLAIQAYGASIVYSEPSDESRENVAQRIIQETEGILVHPNQEPAVIAGQGTIALE 
Human_SR          APDCKKLAIQAYGASIVYCEPSDESRENVAKRVTEETEGIMVHPNQEPAVIAGQGTIALE 
At_SR             APKCKVDNVIRYGGKVIWSEATMSSREEIASKVLQETGSVLIHPYNDGRIISGQGTIALE 
Hv_SR             APACKVENVRRYGGQVIWSDVTMESRESIAKKVQEETGAILIHPFNDKYTISGQGTVCLE 
Aplysia_DAR1      APDVKKNAIRGYGAELLECGPKPSDRNEACDKVQDDRNFELIPPYDHVDVIAGQGTIAVE 
yeast_SR          APEAKVAATKGYGGQVIMYDRYKDDREKMAKEISEREGLTIIPPYDHPHVLAGQGTAAKE 
                  **  *      **..::      ..*:.  ..: :     :: * :.   ::**** . * 
 
Mouse_SR          VLNQVPLVDALVVPVGGGGMVAGIAITIKALKPSVKVYAAEPSN--ADDCYQSKLKGELT 
Rat_SR            VLNQVPLVDALVVPVGGGGMVAGIAITIKTLKPSVKVYAAEPSN--ADDCYQSKLKGELT 
Human_SR          VLNQVPLVDALVVPVGGGGMLAGIAITVKALKPSVKVYAAEPSN--ADDCYQSKLKGKLM 
At_SR             LLEQIQEIDAIVVPISGGGLISGVALAAKSIKPSIRIIAAEPKG--ADDAAQSKVAGKII 
Hv_SR             LLEQVPEIDTIIVPISGGGLISGVTLAAKAINPSIRILAAEPKG--ADDSAQSKAAGRII 
Aplysia_DAR1      LLEQVPFLDAILVPISGGGMSSGICIAAKTIKPDIKIFIVAPKGKRLEECLRTGKRPWEG 
yeast_SR          LFEEVGPLDALFVCLGGGGLLSGSALAARHFAPNCEVYGVEPEA--GNDGQQSFRKGSIV 
                  :::::  :*::.* :.***: :*  :: : : *. .:  . *.    ::  ::        
 
Mouse_SR          PNLHPPETIADGVK-SSIGLNTWPIIRDLVD-DVFTVTEDEIKYATQLVWGRMKLLIEPT 
Rat_SR            PNLHPPETIADGVK-SSIGLNTWPIIRDLVD-DVFTVTEDEIKYATQLVWERMKLLIEPT 
Human_SR          PNLYPPETIADGVK-SSIGLNTWPIIRDLVD-DIFTVTEDEIKCATQLVWERMKLLIEPT 
At_SR             T-LPVTNTIADGLR-ASLGDLTWPVVRDLVD-DVVTLEECEIIEAMKMCYEILKVSVEPS 
Hv_SR             K-LPATSTIADGLR-AFLGDLTWPVVRDLVD-DVIVVDDNAIVDAMKMCYETLKVAVEPS 
Aplysia_DAR1      P-PQYLDTIADGIRLQQTGYITTPILMELAEKDVFEMSDEEIIEGMKFSFERMKLVIETA 
yeast_SR          H-IDTPKTIADGAQTQHLGNYTFSIIKEKVD-DILTVSDEELIDCLKFYAARMKIVVEPT 
                        .***** :    *  * .:: : .: *:. : :  :    ::    :*: :*.: 
 
Mouse_SR          AGVALAAVLSQHFQTVS--PEVKNVCIVLSGGNVDLTS-LNWVGQAERPAPYQTVSV 
Rat_SR            AGVGLAAVLSQHFQTVS--PEVKNICIVLSGGNVDLTS-LSWVKQAERPAP------ 
Human_SR          AGVGVAAVLSQHFQTVS--PEVKNICIVLSGGNVDLTSSITWVKQAERPASYQSVSV 
At_SR             GAIGLAAVLSNSFRNNPSCRDCKNIGIVLSGGNVDLGSLWDSFKSSK---------- 
Hv_SR             GAIGLAAALSDEFKQSSAWHESSKIGIIVSGGNVDLRVLWDSLYK------------ 
Aplysia_DAR1      AGASVAAAFSDRLRKMD--PDLKNVGVILCGGNLDIENLPF---------------- 
yeast_SR          GCLSFAAARAMKEKLKN-----KRIGIIISGGNVDIERYAHFLSQ------------ 
                  .  ..**. :   :        ..: :::.***:*:                      
 
Figure 2.5 The alignment of eukaryotic serine racemase proteins. The CLUSTALW program with 
Biology Workbench at http://workbench.sdsc.edu was used to perform the alignment. 
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Figure 2.6 Twenty six characterized enzyme sequences were aligned using Clustal W program 
(http://seqtool.sdsc.edu) and the resulting alignments were displayed as inferring evolutionary tree by Phylip’ 
Drawgram. TDH: threonine dehydratase; SDH: serine dehydratase; AST: aspartate aminotransferase; SR: serine 
racemase; DR: aspartate racemase; AR: alanine racemase;  ER: glutamate racemase; DAR1: d‐amino acid 
racemase 1; D.sp DR (dbj_BAA12209.1); Ph DR (NP_142620.1); E. faecium DR (ZP_05666819); A. pyrophilus ER 
(AAF25672.1). C. glutamicum ER (NP_601711.1); bivalve DR(BAE78960.1); DAR1(A. californica D‐amino 
acid racemase 1, AC_HM776055); At SR (dbj_BAE72067.1); Hv SR (dbj_BAF63026.1); mouse SR(NP_001156783);
rat SR(NP_942052); human SR(NP_068766); yeast SR (GI:71041740); Archaea SR (dbj_BAE54303.1);  E. c
biosynthetic TDH (NP_418220); AcSDH (gb_AAU05774.1); rat SDH(NP_446414); yeast SDH (gb_AAA35040.1); 
mouse DR (30); mouse AST(AAA37263); human AST (S29028);At DR (NP_200593.2); B. stearothermophilus AR 
(P10724.2); prawn AR (dbj_BAH22617.1); E. gallinarum (AAD22403.1); yeast AR (O59828); S. dysenteriae AR 
(BAB71770.1).  
 
oli 
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3.1 Introduction  
D-serine (D-Ser) and D-aspartate (D-Asp) are endogenous molecules with known or putative 
cell-to-cell signaling activities in the CNS. D-Ser is predominantly found in forebrain 
structures (1), and acts as a co-agonist of the NMDA receptor, regulating activity at its glycine 
modulation site (2)}. Converted from L-serine (L-Ser) by the pyridoxal 5'-phosphate (PLP)-
dependent serine racemase (SerR) in astrocytes (3), D-Ser can be degraded by D-amino acid 
oxidase (DAO) (4) and acts as a novel glial neurotransmitter/neuromodulator (5, 6). 
Abnormal levels of SR and DAO have been observed in schizophrenia patients (7-9), 
suggesting a connection between D-Ser levels and brain function, including mental illness.  
 
In contrast to D-Ser, D-Asp is widely distributed in animals. It has been found in the brain, 
retina, and endocrine and exocrine tissues of both vertebrates and invertebrates (10). D-Asp 
displays a temporal pattern during animal development, beginning with transient high levels 
between embryonic and early postnatal stages, and rapidly declining to trace levels in most 
tissues in young adults (4, 11). Interestingly however, as animals mature, D-Asp is found at 
increasing levels in endocrine tissues (12). The enzyme required for the biosynthesis of D-Asp 
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in the brain was not identified until recently, when the first mammalian aspartate racemase, 
DR, was cloned and characterized (13), although, how much this enzyme accounts for overall 
D-Asp synthesis is unclear. While the mechanism by which D-Asp forms remains under 
investigation, its catabolism is well understood and occurs through the enzyme D-aspartate 
oxidase (14, 15).  
 
Efforts to understand D-Asp function are also ongoing. Indirect evidence points to hormonal 
roles (10), whereas other studies have shown its involvement in vision (16), embryonic 
development (17, 18), learning and memory (19), and neurogenesis (13). Several groups, 
including ours, have proposed that D-Asp can act as a neurotransmitter (12, 14, 20-22).. 
Further research is required to elucidate the physiological role of this intriguing signaling 
molecule. 
 
Clearly, many questions remain about D-Asp formation, regulation and ultimately, its function; 
uncovering the answers will require having knowledge of enzymatic D-Asp biosynthesis. 
Although the D-Ser biosynthesis pathway was described in 1999 (3), as noted, DR, the first D-
Asp racemase enzyme from the animal brain, was just recently reported (13). DR converts L-
Asp to D-Asp and its knockdown reduces newborn neuron survival and dendritic arborization 
in adult mouse hippocampus. In invertebrates, significant quantities of D-Asp are also found 
in nervous and endocrine tissues, indicating a potentially conserved D-Asp signaling pathway 
among Metazoan. However, the origin of the D-Asp in these tissues has not been clarified, nor 
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has a DR-like enzyme been reported in A. californica. So far, the only invertebrate Asp 
racemase described, SbAspR, was isolated from the foot muscle of the bivalve Scapharca 
broughtonii (23). But it is unknown if the enzyme is also present in bivalve nervous and 
endocrine systems. In a prior study (24), we detected high levels of D-Asp (% D/L + D) in the 
F-, C- and G-clusters of the cerebral ganglion of the A. californica CNS, with the highest D-
Asp content (85%) found in the insulin-producing F-cluster cells. We also observed enzyme 
activity in the cerebral ganglion that could transfer [14C] from L-Asp to D-Asp in radioisotope 
pulse-and-chase experiments (21).  
  
In this report, we describe the cloning of an Asp racemase gene, dar1, from the A. californica 
CNS, the characterization of a DAR1 protein by enzyme assay, and examination of CNS 
enzyme localization. Racemase assays were performed using small-volume capillary 
electrophoresis (CE) with laser-induced fluorescence (LIF) detection, selected because the 
methodology is well suited for separating chiral amino acids from small-volume samples (25, 
26). We characterized the enzyme’s activity and show that DAR1 converts L-Asp to D-Asp, 
and vice versa, with a much smaller Km for L-Asp substrate than for D-Asp substrate. The 
enzyme also exhibits Ser racemase activity with a similar Km for both L-Ser and D-Ser 
substrates. The distribution of DAR1 in A. californica indicates it is found in tissues 
previously shown to have significant levels of D-Asp. Based on this dual racemase activity, 
the same tissues have been characterized for D-Ser, and both D-Ser and D-Asp are shown to 
co-localize.  
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3.2 Materials and Methods 
3.2.1 Experimental Animals 
Adult Aplysia californica (125–250 g) were purchased from the Aplysia Research Facility in 
Miami, FL. Animals were kept in an aquarium of artificial sea water (460 mM NaCl, 10 mM 
KCl, 10 mM CaCl2, 22 mM MgCl2, 6 mM MgSO4 and 10 mM HEPES, pH 7.8) with constant 
aeration at 14–15 °C and were used within two weeks of arrival. For dissection, animals were 
anesthetized with an intraperitoneal injection of MgCl2 solution (390 mM) at 30–50 % of 
body weight (v/w), and the interconnected CNS ganglia removed with surgical tools. The 
ganglia were either immediately processed for RNA isolation, total protein extraction or 
amino acid extraction; or treated with 1% protease Type IX (Sigma-Aldrich) in artificial sea 
water containing 100 units/ml penicillin G, 100 µg/ml streptomycin, and 100 µg/ml 
gentamicin for 1 h at 34 °C to aid in the removal of connective tissues prior to CNS 
immunohistochemistry staining. 
 
3.2.2 cDNA Cloning of the dar1 Gene 
The RNA preparation and DNA cloning reagents were purchased from Invitrogen unless 
otherwise specified. Chemicals were purchased from Sigma-Aldrich and the DNA oligos 
from IDT and the W.M. Keck Center for Comparative and Functional Genomics of the 
University of Illinois at Urbana-Champaign. A. californica genomic searches for potential 
amino acid racemase genes were conducted at the NCBI website 
(http://www.ncbi.nlm.nih.gov) using the SbAspR protein sequence (GeneBank accession: 
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BAE78960) as the search query. The target gene found from the BLAST search was named 
dar1. The cDNA sequence of the dar1 was cloned from A. californica CNS ganglion 
poly(A)+ RNA templates prepared by TRIzol Reagent and Dynabeads by conventional RT-
PCR, 5' RACE and 3' RACE cloning techniques using the GeneRacerTM SuperScript III 
module kit and following product instructions. Gene specific primers (GSPs) for RT and PCR 
reactions were created from the dar1 gene and high fidelity DNA polymerases were used for 
the PCR reactions. PCR products of interest were cloned into pCR4.0-TOPO vector, 
transformed into TOP10 cells and sequenced. Three independent clones were obtained which 
covered the complete cDNA sequence of the dar1 gene. Clone 3 contained almost the 
complete dar1 protein coding sequence except for the last 15 nucleotides (nt). Clone 23 was 
produced by 5' RACE and contained the 5' UTR and a partial coding sequence overlapping 
with the 5' end of clone 3 by 882 nt. Clone 108 was produced by 3' RACE and contained the 
3' UTR and a partial protein coding sequence overlapping the 3' end of clone 3 by 282 nt.  
From the sequence information obtained from these three clones, two GSP primers were 
designed and used to clone the entire dar1 ORF by standard RT-PCR from the Aplysia CNS 
ganglion poly (A)+  with Platinum Pfx DNA polymerase. The final ORF clone was named T90.   
 
The primers used for the RT and PCR reactions include the following. For clone 3 cloning: 
GeneRacerTM Oligo dT for RT; GSP 5'-GTGACACACTCCAGTGGGAAC-3' (GSP forward) 
and 5'-CTCAATGTCCAGATTCCCACC-3' (GSP reverse) with pfu Turbo DNA polymerase 
(Agilent Technologies) and the following thermal conditions: 94 °C for 2 min for 1 cycle; 
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94 °C for 30 sec, 50 °C for 30 sec and 72 °C for 1 min for 30 cycles; 72 °C for 10 min for 1 
cycle. For clone 23 cloning, GeneRacer kit (Invitrogen) was used using RNA ligase-mediated 
5’ RACE.  Aplysia CNS mRNA was first dephosphorylated with Calf Intestinal Phosphatase 
and then treated with Tobacco Acid Pyrophosphatase followed by ligation with GeneRacer 
RNA Oligo to the 5’ end of the mRNA. The decapped and ligated mRNA was reverse 
transcribed with GSP reverse primer 5'-CTCAATGTCCAGATTCCCACC-3' and 
SuperscriptTM III transcriptase at 55 °C for 60 min.  The first strand cDNA produced from the 
RT was amplified by PCR with GSP reverse primer 5'-AGCAGCGGCAACCGACGCCCC-3’ 
and commercial GeneRacerTM 5' Primer 5’-CGACTGGAGCACGAGGACACTGA-3’ as 
forward primer and Platinum® pfx DNA polymerase. The PCR thermal conditions used were: 
94 °C for 5 min for 1 cycle; 94 °C for 30 sec, 69 °C for 30 sec, 68 °C for 1.5 min for 35 
cycles; 68 °C for 10 min for 1 cycle.  For clone 108 (3’ UTR clone): DNase treated mRNA 
was used as template of RT reaction with GeneRacerTM Oligo dT and SuperscriptTM III 
enzyme, 55 °C for 60 min; for primary PCR, 5'-ATGGCAGCTTCGTGTGGAGTAACTT-3' 
(GSP forward) and GeneRacerTM 3' Primer (reverse), and Platinum® Taq DNA polymerase 
High Fidelity were used with the following touchdown and hot start PCR thermal profile: 
94 °C for 3 min (add 0.5 μl enzyme to each reaction after 1 min at 94 °C) for 1 cycle; 94 °C 
for 30 sec, 72 °C 90 sec for 5 cycles; 94 °C for 30 sec, 70 °C for 90 sec for 5 cycles, 94 °C for 
30 sec, 65 °C for 30 sec, 68 °C for 90 sec for 25 cycles; 68 °C for 10 sec for 1 cycle.  Nested 
PCR was carried with 5'-CCGCCCCAGTACCTGGACACC-3' (GSP forward) and 
GeneRacerTM 3’ Nested Primer (reverse), and Platinum® Taq DNA polymerase High Fidelity 
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with the following PCR thermal profile: 94 °C for 3 min for 1 cycle; 94 °C for 30 sec, 65 °C 
for 30 sec and 68 °C for 1 min for 25 cycles; 68 °C for 10 min.  For T90 cloning: 
GeneRacerTM Oligo dT for RT; forward GSP primer 5'-
GGCATATGGCAGCTTCGTGTGGA-3' (the Ndel site is underlined) and reverse GSP 
primer 5'-CCCTCGAGTCAAAAAGGCAAATTCTCAATGTC-3' (the Xhol site is 
underlined) for open reading frame full-length PCR with Platinum pfx DNA polymerase with 
the following PCR thermal profile: 94 °C for 3 min (hot started) for 1 cycle; 94 °C for 30 sec, 
56 °C for 30 sec, 68 °C for 1 min for 39 cycles; 68 °C for 10 min.   
 
3.2.3 Construction of the dar1 Protein Expression Vector 
The clone T90 plasmid and pET15b bacterial expression vector (EMD Chemicals) were 
double digested with NdeI and XhoI restriction enzymes (New England BioLabs, Inc.). The 
dar1 fragment and cleaved vector were gel-purified, ligated and transformed into TOP10 cells. 
Transformants were mini-screened and sequenced. A sequence-confirmed clone was 
transformed into BL21 (DE3) bacterial cells (EMD Chemicals) to generate the bacterial clone 
15bT90-31. 
 
3.2.4 DAR1 Expression and Purification 
Protein expression and purification reagents were purchased from EMD4Biosciences 
(Gibbstown, NJ) unless specified otherwise. Chemicals were purchased from Sigma-Aldrich 
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(St. Louis, MO).  15bT90-31 bacteria glycerol stock was inoculated in 2 ml LB supplement 
with ampicillin(100 µg/ml) and grown overnight.  The cells were spun down and re-grown in 
250 ml fresh LB with ampicillin at 37 °C for 3 h or until the O.D. 600 reached 0.4–0.5. The 
culture was then cooled down quickly on ice and then transferred to a temperature controlled 
shaker.  The protein expression of dar1 gene was induced by addition of 0.5 mM of isopropyl 
β-D-1-thiogalactopyranoside (IPTG) and the culture was continued at 17 °C for 16 h.  His.tag 
protein purification from the bacterial cells was performed by following the BugBuster Mix 
lysis and nickel-nitrilotriacetic acid (NiNTA) purification product instructions with some 
modifications. Bacterial cells were harvested from overnight culture by centrifugation at 
10,000 x g for 10 min at 4°C.  The cell pellet was lyzed with 10 ml of BugBuster Master Mix 
supplemented with 2 mM DTT and protease inhibitor cocktail following product instruction.  
The cell lysate was cleared by centrifugation at 16,000 x g for 20 min at 4 °C.  The 
supernatant was mixed with 2 ml NiNTA resin  in 10 ml NiNTA Bind Buffer (50 mM NaPO4, 
100 mM NaCl, 1 mM immidazole, 0.5 mM tris-3-carboxyethanol phosphine, or TCEP), pH 
8.0, supplemented with 2 mM DTT and protease inhibitor cocktail (Novagen) and incubated 
with rocking  at 4 °C for 1 h. The resin was then packed into a 24 ml Econo column (Bio-Rad 
Laboratories) by gravity at 4 °C and column purification was performed at 4 °C cold room.  
The column was washed with 40 ml NiNTA Wash Buffer (Bind Buffer with 20 mM 
immidazole) and protein was eluted with 7 ml NiNTA Elution Buffer (Bind Buffer with 250 
mM Immidazole) into a tube with 5 ml Elution Buffer. The eluted protein was concentrated 
down to 2 ml with Amicon Ultra Centrifugal filter (Thermo Fisher Scientific) and subjected to 
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gel filtration chromatography with a HiPrep Sepharcryl 200 HR 16/60 column (GE 
Healthcare Life Sciences) using 50 mM Tris-HCl buffer, pH 8.0 with 2 mM DTT at 1 ml/min 
flow rate and collected protein peaks at 1 ml fractions and tested for enzyme activity.  The 
active fractions were pooled and buffer exchanged to enzyme storage buffer consisted of 50 
mM NaPO4, 150 mM NaCl, pH 8.0, 20% glycerol and 1 mM DTT. Protein concentration was 
determined with BCA assay kit (Thermo Fisher Scientific). Protein molecular size was 
determined with the gel filtration column described above and calibrated with Low Molecular 
Weight Standard kit (GE Healthcare Life Science) with the purification buffer and calculated 
based on peak retention time following product instructions.  Protein molecular weight and 
purity were estimated by SDS-PAGE with 12% Tris-glycine gel (Invitrogen) with Coomassie 
staining. Enzyme activity was determined by serine racemase assay as described below.  
 
3.2.5 Aplysia Tissue Protein Extraction and Western Blot 
Four adult animals were anesthetized and tissues (CNS, ganglion, liver, buccal muscle, 
ovotestis, atrial gland) were dissected and pooled. CNS ganglia were desheathed to remove 
the fibrous connective tissues, as described above, before protein extraction. The desheathed 
CNS and other tissues were quickly frozen in liquid nitrogen and then homogenized with 
TissueRuptor in Qproteome protein preparation lysis buffer (QIAGEN). Total protein was 
extracted from the homogenized lysates by following the Qproteome kit instructions. Protein 
concentration was determined by BCA assay. Proteins were boiled in 1X Lamini buffer 
containing 10 mM β-mercaptoethanol and loaded to 12% Tris-glycine gel and subjected to 
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reducing SDS-PAGE. Resolved proteins were transferred to HybondTM –P (GE Healthcare) 
PVDF membrane, blocked with 5% non-fat Carnation milk (NestléUSA) in Tris-buffered 
saline with Tween (50 mM Tris, 150 mM NaCl, pH 7.6, 0.05% Tween 20), stained with anti-
DAR1 rabbit serum at 1: 30,000 and goat anti-rabbit HRP secondary antibody (Jackson 
ImmunoResearch) at 1: 20, 000. Antibody-treated membrane was reacted with ImmobilonTM 
Western chemiluminescent HRP substrate (Millipore) and exposed to Amersham 
HyperfilmTM (GE Healthcare Life Sciences). 
 
3.2.6 CE-LIF Instrumentation and Sample Analysis 
Separations were performed using an automated P/ACE MDQ CE system equipped with LIF 
detection (Beckman Coulter). The CE system was coupled to an external diode laser 
56ICS426 (Melles Griot) emitting 440 ± 8 nm, with the coupling performed via a fiber optic 
cable (OZ Optics). The laser power was adjusted to 3 mW at the output terminus of the optic 
cable to avoid damage to the photomultiplier tube (PMT). A bandpass filter of 490 ± 15 nm 
(Omega Optical), located prior to the PMT, selects the appropriate fluorescence emission 
band for detection. For separations, uncoated fused-silica capillaries (Polymicro Technologies) 
were used. Capillaries were injected with 0.1 M NaOH at a pressure of 30 psi for 1 min and 
allowed to be primed in NaOH for 25 min before their initial use. Samples were introduced 
into the capillaries by pressure injection of 0.5 psi for 5 sec. The separation buffer for the Asp 
and glutamate (Glu) enantiomers contained 200 mM borate, pH 9.5, with 60 mM sodium 
deoxycholate (SDC) and 40 mM β-cyclodextrin (β-CD) (27). The Ser enantiomer separation 
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buffer contained 75 mM borate, pH 10.5, with 50 mM SDS and 10 mM γ-cyclodextrin (28). 
For chiral alanine (Ala) separation, the inlet buffer consisted of 25 mM phosphate, pH 2.2, 
containing 4% (w/v) sulfated β-CD, and the outlet buffer of 50 mM phosphate, pH 2.2 (29). 
For Asp, Glu, and Ser chiral separations, capillaries of 75 µm inner diameter (ID) and 360 µm 
outer diameter (OD) were used. Capillary total length was 80 cm with an effective length of 
70 cm to the detection window. Separations were carried out by applying 27 kV of normal 
polarity. Between two runs, the capillaries were rinsed with methanol (30 psi, 0.5 min), 0.1 M 
NaOH (30 psi, 1 min), and separation buffer (30 psi, 1 min). For Ala enantiomer separations, 
capillaries of 50 µm ID and 360 µm OD were used with 60 cm total length and 50 cm 
effective length. A reverse polarity of 20 kV was applied for separations. After each run, the 
capillaries were rinsed first with methanol (30 psi, 0.5 min), followed by the inlet separation 
buffer (30 psi, 1 min). CE-LIF results were displayed as electropherograms, which show 
analyte peak fluorescence intensities against analyte migration time from the capillary 
injection site to detection window. For quantitative analysis, the peak areas of amino acid 
analytes and internal control glycine from the CE electropherograms were obtained using 
Origin 8 software (Origin Lab Corporation). In order to obtain analyte concentrations, analyte 
peak areas were divided by glycine peak areas to generate normalized analyte peak area 
values, and converted to concentrations using working curves generated with known 
concentrations under the same experimental conditions.  
 
3.2.7 DAR1 Racemase Assay (non-quantitative assay)  
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Chemicals and reagents for the enzyme assays were of the highest grade available and 
purchased from Sigma-Aldrich unless specified otherwise. Naphthalene-2,3-dicarboxaldehyde 
(NDA) was purchased from Invitrogen. Water was deionized and purified using a Barnstead 
E-PURE purification system (ThermoFisher Scientific) and sterilized by passing through 0.22 
µm filters. Procedures were performed at room temperature unless otherwise noted. The 
racemase assays contained a cofactor mix composed of 20 µM PLP, 4 mM ATP, 2 mM DTT 
and 2 mM MgCl2 in Tris-HCl buffer of various concentrations and pH, depending on the 
specific experiment. To perform each assay, L/D-Asp, L/D-Ser, L-Glu or L-Ala (2.5–200 mM) 
substrates were incubated with 1–10 µg of purified DAR1 in 100–150 μl Tris-HCl buffer 
( 25–50 mM, pH 7.0–8.5) and cofactor mix at 30 °C for 2–4 h. Negative controls contained 
heat-inactivated enzyme or no substrates. At the end of the incubation period, glycine (3–5 
mM) was added to each reaction and used as an internal control for subsequent sample 
treatments and analyses. Enzyme was removed by either TCA precipitation or the alternative 
filtration method described below, before amino acid derivatization for CE analysis. The TCA 
precipitation method was used for the Ser and Asp assays. To remove the enzyme, 5% cold 
TCA was added to the reaction samples and incubated for 10 min on ice followed by 
centrifugation at 10,000 × g for 10 min. TCA was then removed from the samples by two 
extractions with equal volume of water/saturated ether. Enzyme can also be removed from an 
assay sample by centrifugation in a Pierce® Concentrator 7ml/9K molecular-weight cutoff 
(ThermoFisher Scientific) for 30 min to collect protein-free filtrate. Protein-free samples were 
diluted in 50 mM borate buffer, pH 9.4, to appropriate volumes so that amino acids were 
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derivatized with an 8× excess of NDA and 20× excess of potassium cyanide (KCN) in 50 mM 
borate buffer, pH 9.4, for 45 min. The reaction was stopped by diluting 1:10 with 50 mM 
borate buffer, pH 8.5, and immediately frozen on dry ice. Samples were then subjected to CE-
LIF analysis within 24 h. 
 
3.2.8 Enzyme Kinetics Assay (quantitative assay)  
A series of concentrations (2.5–80 mM) of Ser or Asp substrates were incubated with 1–2 µg 
of purified enzyme in 100 µl reactions in 50 mM Tris-HCl buffer, pH 8.5, for Ser reactions, or 
pH 8.0 for Asp reactions, containing cofactor mix at 30 °C for 70–150 min. At the end of the 
incubations, 5 mM glycine was added to each reaction as an internal control. In addition, L-
Ala was added to the Ser samples and L-Glu was added to the Asp samples so that the total 
amino acid concentrations in all reactions were equal to the highest substrate concentrations. 
The enzymes were immediately removed by centrifugal filtration as described above. The 
protein-free samples were then diluted to appropriate concentrations with 50 mM borate 
buffer, pH 9.4, so that 800 μM of the total amino acids were derivatized with 6.4 mM NDA 
and 16 mM KCN in a 10 µl reaction for 60 min. The reactions were stopped by 1:10 dilution 
with 50 mM borate buffer, pH 8.5, and quickly frozen on dry ice until CE-LIF analysis. The 
quantity of amino acid products was calculated from the linear function produced by a 
standard amino acid calibration curve by co-assaying standard amino acids without enzyme 
with samples containing enzyme. The enzyme catalysis velocity is defined as a µmole product 
formed by 1 mg of enzyme during a 1 h reaction time at 30 °C under assay-described buffer 
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conditions. The inverse enzyme velocities were plotted against inverse substrate 
concentrations and fitted to a linear model using Microsoft Excel to generate Lineweaver-
Burk Plots. The Km and Vmax values were calculated from the inverse X- and Y- intercepts of 
the plots. 
 
3.2.9 Aplysia CNS Whole-mount Immunohistochemistry  
A rabbit polyclonal antibody against purified full-length DAR1 was generated by the 
Immunological Resource Center, University of Illinois at Urbana-Champaign.  A New 
Zealand White female rabbit of 3-6 month old was immunized via s.c. with 500 µl - 1 ml 
antigen emulsion composed of DAR1 and adjuvant at 1:1 ratio (v/v) four times, once every 
three weeks and then bled out by cardio-puncture method.  For primary immunization, 500 µg 
of antigen and Titermax (SIGMA) adjuvant was mixed by sonication to make antigen 
emulsion; and 250 µg DAR1 and Incomplete Freund’s Adjuvant emulsion was used for all 
subsequent immunizations. All animal work was performed in compliance with federal, state 
and university guidelines for animal care and usage. Normal goat serum and rhodamine Red-
X-conjugated goat anti-rabbit IgG (H+L) secondary antibody were purchased from Jackson 
ImmunoResearch (West Grove, PA). Paraformaldehyde was purchased from Electron 
Microscopy (Sciences Hatfield, PA). The periesophageal ring and abdominal ganglia without 
connective tissue (or desheathed) were stretched onto Sylgard in 35 mm Petri dishes and fixed 
with paraformaldehyde as described by Llewellyn-Smith et al. (30). The tissues were rinsed 
with PBS to remove the fixative, blocked overnight with 10% normal goat serum, and then 
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incubated with anti DAR1 rabbit antibody (1:1000 diluted) for 7 days. The samples were 
washed with 10 mM phosphate buffer, pH 7.5, containing 154 mM NaCl, 1% BSA, 0.25 mM 
thimerosal and 2% Triton X-100 for 3 days, incubated with the secondary antibody (1:500 
dilution) for 3 d in the dark, and washed with the phosphate buffer without Triton X-100 for 3 
days. Control samples were stained with either primary antibody or secondary antibody alone 
or pre-immune serum plus secondary antibody. The post-staining preparation for light 
microscopy visualization was performed as described by Fujisawa et al. (31). Basically, the 
samples were dehydrated for 30 min in each of the following ethanol solutions by order: 30 %, 
60 %, 90 %, 100% and 100 %. The samples were then cleared by soaking in 98 % methyl 
salicitate for 15 min and then incubated at 4 °C for overnight. The samples were mounted on 
glass slides and kept in the dark until photographed within a week with a Zeiss Axiovert 
200M inverted research-grade microscope equipped with a Roper Scientific Cascade 512B 
EMCCD camera and Zeiss Axiovision software. The camera obtained black/white and color 
fluorescence images with appropriate filters; the software was used to perform Z-stacking, 
time-lapse and tiling. The rhodamine images were obtained via 560 mm excitation and 620 
nm emission. 
 
3.2.10 Detection of D-Asp and D-Ser in Aplysia CNS Ganglion Clusters 
Aplysia californica cerebral ganglion clusters were dissected from anesthetized animals and 
immediately placed into 100–200 µl of 0.1 N HCl. The cells were homogenized manually 
with a glass homogenizer followed by sonication for 15 min in a water-bathed sonicator. The 
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materials were then centrifuged at 10,000 × g for 10 min at 4 °C and the supernatants dried 
down in a microcentrifuge under vacuum. The dried materials were reconstituted with 10 μl 
of 100 mM borate buffer, pH 9.4. Samples (0.5 μl) were then derivatized with 1 μl of 20 mM 
NDA and 1 μl of 20 mM KCN for 1 h. The derivatized samples were diluted 5–20 fold with 
75 mM borate buffer, pH 10.5, for Ser separation, or 200 mM borate buffer, pH 9.5, for Asp 
separation. The diluted samples were injected into capillary by pressure at 0.5 psi for 5 sec 
and separated under 27 kV with normal polarity.  
 
3.3 Results 
3.3.1 Cloning of dar1 Full-length cDNA  
In order to locate an aspartate racemase in the A. californica nervous system, we searched the 
online A. californica genome database and discovered a candidate gene (gi-225479051), 
naming it dar1. We cloned the full-length cDNA of the dar1 gene, including the protein 
coding sequence (deposited in GenBank HM776055), and the 5' UTR and 3' UTR from 
poly(A)+ RNA, by using conventional RT-PCR, 5' RACE and 3' RACE cloning techniques. 
The cDNA sequence and protein translation of DAR1 are shown in Fig. 3.1. The cDNA 
includes a 20 nt 5' UTR, 978 nt coding sequence and 241 nt 3' UTR. The 3' UTR contains a 
polyA tail of 23 adenines and two overlapping AAATAA polyadenylation signals. In total, 
the cDNA contains 1220 nt and codes for a 325 amino acid-long protein. At the protein level, 
DAR1 shares a 55% sequence identity to the bivalve aspartate racemase, and more than 40% 
to human, rat and mouse brain serine racemases. A multiple sequence alignment of these five 
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related proteins is shown in Fig. 3.2. The proteins have similar lengths, ranging from 325 to 
340 amino acids, and share multiple conserved regions, including a putative PLP-binding 
motif near the N-terminus around the DAR1 PLP-binding Lys57 (32) and the DAR1 PLP-
binding stabilizing clusters, 80Ser-Ser-Gly-Asn-His and 183Ser-Gly-Gly-Gly (33).  
  
3.3.2 DAR1 Expression and Purification  
We cloned the dar1 ORF into a microbial expression vector, over-expressed the gene as a 
soluble recombinant protein with an N-terminal 6xHis.tag in E. coli, and purified it for 
functional studies. The recombinant protein was only expressed under ITPG induction and 
purified from bacterial cell lysate to near homogeneity using NiNTA affinity purification and 
gel filtration chromatography Fig. 3.3 The recombinant DAR1 exhibited an electrophoresis 
mobility of 37 kDa in a reducing SDS-gel—a result consistent with the predicted molecular 
weight of the recombinant protein, but it had a molecular mass of 57 kDa as determined by a 
sizing column. The considerably larger molecular mass than molecular weight indicates that 
DAR1 molecules form homodimers in solution. Dimerization seems to be essential for DAR1 
activity because the protein fraction of 30–35 kDa off the sizing column had little enzyme 
activity (data not shown).  
 
3.3.3 DAR1 Expression in A. californica Tissues  
We raised a rabbit polyclonal antibody against purified recombinant DAR1 and examined 
dar1 expression in A. californica CNS neurons, and liver, buccal muscle, ovotestis and atrial 
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gland tissues by Western blot. As shown in Fig. 3.4, dar1 was expressed as a ~36 kDa protein 
(predicted molecular weight is 35.4 kDa) in the CNS ganglion lysate. The protein was also 
strongly expressed in atrial gland- an exocrine tissue that secrets egg laying peptides, 
moderately in liver, and minimally in buccal muscle and ovotestis when an equal amount of 
total protein was loaded for each tissue sample. However, ovotestis showed a larger band with 
moderate signal which might be from a different transcript.  
 
3.3.4 DAR1 Racemase Activity and Characterization 
I examined DAR1 PLP-dependent racemase activity towards L/D-Asp, L/D-Ser, L-Glu and L-
Ala substrates, and observed enzyme behaviors under different temperatures and buffer pH 
levels, and the effects of ATP/MgCl2 on the enzyme activity. These measurements were 
accomplished with CE-LIF, an approach well suited for chiral amino acid separation and 
detection. Our assay results demonstrated that DAR1 was active towards both Asp and Ser 
substrates and converted these chiral enantiomers in both directions as shown in Fig. 3.5. 
However, DAR1 had no detectable activity when 10 µg of purified enzyme was incubated 
with 100 mM L-Glu or 100 mM L-Ala (D-Glu and D-Ala were not tested) in a 150 µl reaction 
containing 50 mM Tris-HCl, pH 8.0, with cofactors at 30 °C for 3 h, a condition where Asp 
and Ser conversion were easily observed. 
 
DAR1, like other PLP-dependent racemases, requires the cofactor PLP for its activity. 
Purified enzyme appeared greenish yellow and absorbed light at 420 nm, a characteristic of 
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PLP-bound enzyme (33). The absorption peak disappeared after the enzyme was incubated for 
10 min at room temperature with 2 μM aminooxyacetic acid (AOAA), a PLP-inactivating 
reagent (data not shown). The enzyme did not lose color after a 48 h dialysis, indicating a 
high affinity between the enzyme and PLP. AOAA inhibited the conversion by DAR1 of D-
Ser and D-Asp from their corresponding enantiomer (Fig. 3.6A). The thermal stability profile 
of DAR1 is shown in Fig. 3.6B. The enzyme activity increased between 14–45 °C and started 
to decrease at 50 °C for both the Ser and Asp conversions. We examined the modulating 
effects of ATP and MgCl2 on DAR1 racemase activity (Fig. 3.6 continued). MgCl2 (2 mM) 
had only a small effect on enzyme racemase activity but ATP (4 mM) significantly increased 
enzyme activity. When both effectors were present, the enzyme showed the largest activity for 
the D-Asp and D-Ser conversions. The ATP and MgCl2 concentrations were not optimized for 
DAR1; we chose the concentrations based on published research on Ser and Asp racemases 
(34, 35). Finally, Fig. 3.6 continued showed the pH-dependent DAR1 L-Asp racemase 
activity (A) and L-Ser racemase activity (B). The enzyme showed little racemase activity 
below pH 6.5 (data not shown) and an increasing activity between pH 7.0–8.5 in 50 mM Tris-
HCl buffer. 
 
3.3.5 Enzyme Kinetics 
The DAR1 Asp and Ser racemase kinetics linear curves are shown as Lineweaver-Burk Plots 
in Fig. 3.7. Analyzing the linear fits, the Km (mM) was determined to be 8 ± 2 (SD) for L-Asp, 
94 ± 30 for D-Asp, and 15 ± 4 and 16 ± 2 for L-Ser and D-Ser, respectively; the Vmax (µmole 
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hr-1 mg-1) for the same substrate order was determined to be 3.3 ± 0.8, 7.9 ± 1, 11 ± 1.6 and 15 
± 3, respectively.  
 
3.3.6 Co-localization of DAR1 and D-amino Acids in the A. californica CNS 
We raised a rabbit polyclonal antibody against DAR1 and used it to perform whole-mount 
(versus section) immunohistochemistry with A. californica CNS material. We stained the 
isolated CNS, including the buccal, pleural, pedal, abdominal and cerebral ganglia, and their 
connective and peripherally extending nerves. The immunohistochemistry experiments 
revealed a highly localized distribution of DAR1 protein in the CNS (Fig. 3.8). The antibody 
exclusively stained F-, C-, G- and B-cluster cells located in the middle region of the fused 
cerebral ganglia. The staining was specific; controls without primary or secondary antibody 
produced only background signal (data not shown). The other ganglia showed only 
background staining, except for a group of 3–4 unidentifiable neurons in the vicinity of B1 
and B2 landmark neurons in the buccal hemiganglia and a lone neuron in the abdominal 
hemiganglia.  
 
While our prior research characterized D-Asp, we had not performed D-Ser separations; the 
optimum CE conditions are distinct for the two amino-acid pairs. Thus, we have re-measured 
both D/L-Asp and D/L-Ser within several CNS structures. As demonstrated as the CE-LIF 
electropherograms in Fig. 3.9, not only was a high level of D-Asp (more than L-Asp) once 
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again detected, a significant amount of D-Ser (less than L-Ser) was also found for the first time 
in the F/C-clusters.  
 
3.4 Discussion 
We have characterized a novel racemase enzyme from A. californica. Homology data 
suggests that the known mammalian and our new molluskan amino acid racemase share a 
conserved structural similarity. Intriguingly, although a similar enzyme has not been found in 
mammals, a distinct aspartate racemase (DR) was recently identified (13). DR has less than 
20% identity to the other five racemase proteins, and it lacks the similar PLP binding and 
stabilizing sequences shared by other racemase groups. Based on our phylogenetic analysis, 
Ser racemases are closer to serine dehydratase (EC 4.3.1.17), while DR is closer to glutamate-
oxalacetate transaminase enzyme (EC 2.6.1.1). It appears that DAR1 and DR are distinct Asp 
racemases from animal brains. Intriguingly, DAR1 and mammalian SerR are closely related 
and yet the mammalian DR is distinct. Are there other animal amino acid racemases that are 
still unknown? Given recent reports of high levels of D-Glu (36) and D-Ala (37) in rat brain, 
this appears a certainty. It will be interesting to determine their structures and how they fit 
within the growing Metazoan CNS amino acid racemase family. 
  
After expressing and purifying DAR1, we tested its activity and ability for racemizing the 
amino acids that have previously been shown to be present at high levels in animal brains—
Asp, Ser, Glu, and Ala (38, 39). The enzyme was active towards Ser and Asp enantiomers but 
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showed no activity towards Glu and Ala. To our best knowledge, DAR1 is the first 
characterized eukaryotic racemase that can catalyze the racemization of two substrates. The 
enzyme is PLP-dependent and appears to require dimerization for activity. Homodimers have 
been observed with mouse SerR and SbAspR (32, 34, 40). The recombinant DAR1 appears to 
be heat-tolerant under the assay conditions used. As with most protein enzymes, its activity 
increases with increasing temperatures. The enzyme shows a wide temperature range of 
activity, between 14 °C and 45 °C.  
  
We examined ATP and MgCl2 effects on DAR1 racemase activity and found that both 
reagents, especially ATP, are important for promoting enzyme racemase activity, and they act 
more effectively together than they do alone. It has been proposed that ATP and MgCl2 exert 
allosteric regulatory effects on mouse SerR by lowering enzyme Km (34). Although not 
examined, the same regulatory mechanisms might be at work for DAR1. Studies by other 
groups have also shown that other nucleotides and bivalent cations could regulate animal Asp 
and Ser racemase activities. As examples, besides Mg2+, Ca2+ and Mn2+ have been shown to 
promote mouse SerR activity (34) and AMP promoted SbAspR activity, but ATP reduced it 
(35). It is interesting that while ATP has a positive effect on DAR1 activity, the same 
nucleotide showed an inhibitory effect on SbAspR activity. The opposite effects of ATP on 
the two closely related mollusk aspartate racemases indicate that the enzymes may have 
different physiological functions. In addition, SbAspR might have a role in energy 
metabolism under anoxic conditions in bivalve muscle tissues (23).  
66 
 
  
The enzyme is more active under alkaline condition. Both Ser and Asp activities were low 
below pH 6.5, while increasing between pH 7.0 and pH 8.5 in 50 mM Tris-HCl. The pH 
profile is similar to that of a mouse SerR (3) and distinct from that reported for SbAspR (23), 
where the enzyme activity started to decrease above pH 8.5. We found that the optimal 
buffers were 25 mM Tris-HCl, pH 8.5, for L-Asp conversion and 50 mM Tris-HCl, pH 9.0, 
for L-Ser conversion (data not shown), suggesting that ion strength and pH can affect enzyme 
efficiency for a particular substrate. We chose 50 mM Tris-HCl, pH 8.5, for most of our 
assays in order to simplify the experimental procedures.  
  
We determined the Km and Vmax for the four racemase reactions catalyzed by DAR1 as shown 
in Fig. 3.7. The kinetic data revealed the following. First, the enzyme favored L-Asp over D-
Asp—the smaller the Km, the higher affinity a substrate has for an enzyme—and the Km for  L-
Asp substrate was about 10× smaller than that for D-Asp substrate. Although the enzyme had 
twice as large a Vmax for L-Asp production, L-Asp is 10× more competitive than D-Asp for 
binding to the enzyme. Therefore, the enzyme was more efficient in producing D-Asp from L-
Asp than vice versa. Differing from the Asp kinetics, Ser kinetics are comparable with both 
substrates. But the Km values for both forms of Ser were still 4× larger than that for L-Asp. 
Based on the Km values, the enzyme had the highest affinity towards L-Asp, followed by L-
Ser/D-Ser, and then D-Asp.  However, more studies are required to understand the 
physiological meaning of these kinetics parameters.   
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The selected presence and relatively sparse distribution of DAR1 within the A. californica 
CNS, specifically several cerebral ganglion clusters and isolated single neurons in the buccal 
and abdominal ganglia, suggests that the enzyme serves a specific function within these areas 
(and does not have a more general "cellular housekeeping" role). At this point, we have 
determined that DAR1 is capable of synthesizing D-Asp and it is localized to specific 
structures. Using CE-LIF we measured the presence of D-Ser and D-Asp in the cells 
containing the enzyme to determine if they co-localize. It is particularly telling that the 
enzyme was present in the F-, C- and G-clusters where high levels of D-Asp content were 
previously reported (21, 22), we now confirm the co-localization of D-Ser and D-Asp in these 
structures. The correlation of DAR1 and its products supports our determination that the 
enzyme is involved in the actual biosynthesis of D-Asp and D-Ser. Several years ago, we 
hypothesized that D-Asp was a neurotransmitter in the A. californica CNS (22). Since then, 
we have accumulated evidence of D-Asp release from and uptake by the cerebral ganglia. The 
finding of a D-Asp biosynthesizing enzyme in the cerebral ganglia substantiates this 
hypothesis.  
 
3.5 Conclusions 
We have isolated a novel racemase from A. californica neuronal tissues, characterized its 
biochemical features, and validated its ability to form D-Asp and D-Ser. DAR1 can catalyze 
racemization reactions between Asp and Ser enantiomers with differing kinetics. The enzyme 
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Km and Vmax values suggest a substrate preference order of L-Asp > L-Ser ≥ D-Ser > D-Asp. 
DAR1 is the first Asp and Ser racemase discovered in an invertebrate brain and the first 
eukaryotic dual Asp/Ser racemase described. Using whole-mount CNS tissue staining with 
DAR1 antibody, we localized DAR1 to the central region of the cerebral ganglia where the F- 
and C-clusters are situated. These clusters contained a high level of D-Asp and a significant 
amount of D-Ser. The co-localization of the enzyme with the four amino acids demonstrates 
that DAR1 plays a role in the biosynthesis of D-Asp and/or D-Ser in the F/C-clusters. Future 
work will examine the roles of D-Asp and D-Ser in cell-to-cell communication and study the 
interactions between these two putative signaling molecules.  
 
 
 
 
 
 
 
 
3.6 Figures 
 
                        -1 
-20   ggtcaaatagcaactaaacaATGGCAGCTTCGTGTGGAGTAACTTTCGTCGATGTGCTC 39                            
                          M  A  A  S  C  G  V  T  F  V  D  V  L          
40    AAAGCACTGGAAAGGATTTCACCGTTCATTCACAAAACTCCTATCTTCACATCTGAACAA 99         
      K  A  L  E  R  I  S  P  F  I  H  K  T  P  I  F  T  S  E  Q     
100   GCAAATAGGAAATGTGGACGACAACTGTTCTTCAAATGCGAAAACTTTCAAAAGTCGGGT  159  
      A  N  R  K  C  G  R  Q  L  F  F  K  C  E  N  F  Q  K  S  G   
160   TCATTTAAAGCCCGTGGAGCGTTGAATGCCGTTTTGAAGTGTCAGCAAGTGAAACCAAAC 219  
      S  F  K  A  R  G  A  L  N  A  V  L  K  C  Q  Q  V  K  P  N     
220   GTCAACGGAGTGGTGACACACTCCAGTGGGAACCACGGCCAGGCGCTGGCATGGGCCGCC 279 
      V  N  G  V  V  T  H  S  S  G  N  H  G  Q  A  L  A  W  A  A     
280   CAGCGAGCCAATCTCCCGTGTTGCGTCGTCGTGCCACAGATGGCTCCTGATGTGAAGAAG 339 
      Q  R  A  N  L  P  C  C  V  V  V  P  Q  M  A  P  D  V  K  K   
340   AATGCAATCCGAGGCTATGGAGCAGAGCTGTTGGAATGTGGACCAAAGCCCAGTGACAGA 399 
      N  A  I  R  G  Y  G  A  E  L  L  E  C  G  P  K  P  S  D  R   
400   AATGAGGCTTGTGACAAAGTACAGGACGATAGGAACTTTGAGTTAATTCCCCCTTATGAC 459 
      N  E  A  C  D  K  V  Q  D  D  R  N  F  E  L  I  P  P  Y  D   
460   CACGTGGATGTGATTGCTGGACAGGGCACCATAGCTGTGGAGCTGTTGGAGCAAGTGCCT 519 
      H  V  D  V  I  A  G  Q  G  T  I  A  V  E  L  L  E  Q  V  P   
520   TTCCTGGACGCTATCCTGGTCCCCATCAGTGGAGGTGGGATGTCCTCGGGAATCTGTATC  579          
      F  L  D  A  I  L  V  P  I  S  G  G  G  M  S  S  G  I  C  I     
580   GCTGCCAAGACCATCAAACCGGACATCAAAATATTCATCGTGGCTCCTAAAGGGAAGCGA 639 
      A  A  K  T  I  K  P  D  I  K  I  F  I  V  A  P  K  G  K  R     
640   CTGGAGGAATGTTTGAGAACAGGCAAGCGTCCTTGGGAAGGGCCGCCCCAGTACCTGGAC 699 
      L  E  E  C  L  R  T  G  K  R  P  W  E  G  P  P  Q  Y  L  D   
700   ACCATTGCAGACGGCATCCGGCTACAGCAGACGGGCTACATCACCACACCCATACTCATG 759 
      T  I  A  D  G  I  R  L  Q  Q  T  G  Y  I  T  T  P  I  L  M   
760   GAACTGGCCGAGAAAGACGTCTTTGAGATGAGTGATGAAGAAATTATTGAAGGAATGAAG 819 
      E  L  A  E  K  D  V  F  E  M  S  D  E  E  I  I  E  G  M  K   
820   TTCAGCTTCGAGAGAATGAAGCTGGTCATTGAGACAGCGGCCGGGGCGTCGGTTGCCGCT 879 
      F  S  F  E  R  M  K  L  V  I  E  T  A  A  G  A  S  V  A  A   
880   GCTTTCTCTGATCGACTACGGAAGATGGACCCGGACTTAAAGAACGTTGGGGTCATTTTG 939 
      A  F  S  D  R  L  R  K  M  D  P  D  L  K  N  V  G  V  I  L   
940   TGTGGTGGGAATCTGGACATTGAGAATTTGCCTTTTTGAagagggtgaggagaggtcgag 999 
      C  G  G  N  L  D  I  E  N  L  P  F  *   
1000  gaagggggtgaggggcaaagttgaggtgggatggtgaggaggggattaagatgaggagtg 1059  
1060  tgagaagggatggttaacaaaaagcagcctcgtggtatccctttaaacaagtaccaacag 1119 
1120  aaaacagcaacaacaaaaatacaaattaaataaataaaacaaactaactaacgaagaaag 1179 
1180  aaagaaagaaacgagagaaaaaaaaaaaaaaaaaaaaaaa  1220 
 
 
Figure 3.1 Complete cDNA sequence and predicted protein sequence of dar1 gene. 5’ UTR: nt ‐20 to nt ‐1 in 
lower case letters; amino acid coding sequence: uppercase single letters; predicted amino acid sequence: single 
letter codes in uppercase; asterisk: stop codon TGA; 3’ UTR: nt 979 to nt 1220 in lower case letters; 
polyadenylation signals: bolded lowercase letters (aataaa).  Underlined sequence: predicted PLP‐binding motif 
with a PLP‐binding residue Lys56 in bold and shade.   GenBank accession number for complete CDS: HM776055.  
Reprinted with permission from reference 41.   
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 Mouse_SR        ---MCAQYCISFADVEKAHINIQDSIHLTPVLTSSILNQ----IAGRNLFFKCELFQKTG 
Rat_SR          ---MCAQYCISFADVEKAHLNIQDSVHLTPVLTSSILNQ----IAGRNLFFKCELFQKTG 
Human_SR        ---MCAQYCISFADVEKAHINIRDSIHLTPVLTSSILNQ----LTGRNLFFKCELFQKTG 
Bivalve_DR      MASKIPQFEVTVTDIKKAYDRISKHILYTPVFTSPTFDRMVGSKAGRQFYFKAENLQKTG 
DAR1            MAASCG---VTFVDVLKALERISPFIHKTPIFTSEQANR----KCGRQLFFKCENFQKSG 
                         ::..*: **  .*   :  **::**   ::      **:::**.* :**:* 
 
Mouse_SR        SFKIRGALNAIRGLIPDTPEEKPKAVVTHSSGNHGQALTYAAKLEGIPAYIVVPQTAPNC 
Rat_SR          SFKIRGALNAIRGLIPDTLEGKPKAVVTHSSGNHGQALTYAAKLEGIPAYIVVPQTAPNC 
Human_SR        SFKIRGALNAVRSLVPDALERKPKAVVTHSSGNHGQALTYAAKLEGIPAYIVVPQTAPDC 
Bivalve_DR      SFKARGALNAI--LCALEREPSLAGVVTHSSGNHGQALAWASKRAGVKCCVVVPKTAPQV 
DAR1            SFKARGALNAV--LKCQQVKPNVNGVVTHSSGNHGQALAWAAQRANLPCCVVVPQMAPDV 
                *** ******:  *     : .  .*************::*::  .: . :***: **:  
 
Mouse_SR        KKLAIQAYGASIVYCDPSDESREKVTQRIMQETEGILVHPNQEPAVIAGQGTIALEVLNQ 
Rat_SR          KKLAIQAYGASIVYSEPSDESRENVAQRIIQETEGILVHPNQEPAVIAGQGTIALEVLNQ 
Human_SR        KKLAIQAYGASIVYCEPSDESRENVAKRVTEETEGIMVHPNQEPAVIAGQGTIALEVLNQ 
Bivalve_DR      KFDAMENYGAEVVKCEPNPTSRKETCEGLAKSRGYKYISSSDDYDVIAGQGTIALELLQQ 
DAR1            KKNAIRGYGAELLECGPKPSDRNEACDKVQDDRNFELIPPYDHVDVIAGQGTIAVELLEQ 
                *  *:. ***.:: . *.  .*::. . : ..     : . :.  *********:*:*:* 
 
Mouse_SR        VPLVDALVVPVGGGGMVAGIAITIKALKPSVKVYAAEPSN--ADDCYQSKLKGELTPNLH 
Rat_SR          VPLVDALVVPVGGGGMVAGIAITIKTLKPSVKVYAAEPSN--ADDCYQSKLKGELTPNLH 
Human_SR        VPLVDALVVPVGGGGMLAGIAITVKALKPSVKVYAAEPSN--ADDCYQSKLKGKLMPNLY 
Bivalve_DR      QPDLDAILVSVSAGGMASGICVYTKNTKSDLKVFLVEPEGKMLEECISKRERLWPNP-PQ 
DAR1            VPFLDAILVPISGGGMSSGICIAAKTIKPDIKIFIVAPKGKRLEECLRTGKRPWEGP-PQ 
                 * :**::*.:..*** :**.:  *  *..:*:: . *..   ::*  .  :    *    
 
Mouse_SR        PPETIADGVKSS-IGLNTWPIIRDLVD-DVFTVTEDEIKYATQLVWGRMKLLIEPTAGVA 
Rat_SR          PPETIADGVKSS-IGLNTWPIIRDLVD-DVFTVTEDEIKYATQLVWERMKLLIEPTAGVG 
Human_SR        PPETIADGVKSS-IGLNTWPIIRDLVD-DIFTVTEDEIKCATQLVWERMKLLIEPTAGVG 
Bivalve_DR      FLDTIADGIILQQCGNKTWPIILELPEKEVITVNNDNIVEAMRFVFARMKLVIEAAAGAT 
DAR1            YLDTIADGIRLQQTGYITTPILMELAEKDVFEMSDEEIIEGMKFSFERMKLVIETAAGAS 
                  :*****:  .  *  * **: :* : ::: :.:::*  . :: : ****:**.:**.  
 
Mouse_SR        LAAVLSQHFQTVSPEVKNVCIVLSGGNVDLTS-LNWVGQAERPAPYQTVSV 
Rat_SR          LAAVLSQHFQTVSPEVKNICIVLSGGNVDLTS-LSWVKQAERPAP------ 
Human_SR        VAAVLSQHFQTVSPEVKNICIVLSGGNVDLTSSITWVKQAERPASYQSVSV 
Bivalve_DR      VAAAMTERFQNFHPEAKKVGIILCGGNVDIEK-LPWTKKDTK--------- 
DAR1            VAAAFSDRLRKMDPDLKNVGVILCGGNLDIEN-LPF--------------- 
                :**.::::::.. *: *:: ::*.***:*: . : :                
 
 
Figure 3.2 Protein sequence alignment of five eukaryotic amino acid racemases. SR: serine racemase; 
DR: aspartate racemase; DAR1: Aplysia d‐amino acid racemase 1; mouse SR(NP_001156783); rat 
SR(NP_942052); human SR(NP_068766); bivalve DR(BAE78960.1); DAR1 (AC_HM776055). Asterisk: 
completely conserved residues; colon: identical residues; period: similar residues. Red box: 
conserved PLP‐binding residue, lysine.  Reprinted with permission from reference 41.   
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Figure 3.3 SDS‐PAGE analyses of DAR1 expression and purification. Denatured and reduced cell 
lysates of bacterial cultures with IPTG (land 1) or without IPTG (lane 3); 2.5 µg NiNTA purified protein 
(lane 5) and 2.5 µg gel filtration purified protein (lane 2); and 5 µg Precision Plus Protein standards 
(lane 4, Bio‐Rad Laboratories, Hercules, CA ) were loaded to 12% Tris‐glycine gel.  The SDS gel was 
stained with Coomassie blue.  Predicated recombinant DAR1 molecular weight is 37.1 kDa. Reprinted 
with permission from reference 41.   
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Figure 3.4 Western analysis of DAR1 expression in Aplysia tissues. Tissue protein lysates of CNS, liver, 
buccal muscle, atrial gland or ovetestis were subjected to reducing SDS‐PAGE.  Ten micrograms of 
each sample were co‐run with Precision Plus Protein Standards in 12% Tris‐glycine gel.  Transfer blot 
was stained with rabbit anti‐DAR1 serum (1: 30,000) and goat anti‐rabbit HRP conjugate (1: 20,000).  
Film was exposed for 5 min.  Predicted native DAR1 protein is 35.4 kDa. Reprinted with permission 
from reference 41.   
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Figure 3.5 DAR1 Asp and Ser racemase activities. CE‐LIF electrophoregrams of enzyme reactions with 
four substrates L‐Asp (a), D‐Asp (b), L‐Ser (c), D‐Ser (d).  L‐Asp/D‐Asp (80 mM), or L‐Ser/D‐Ser (10 mM) 
was incubated with 1 µg enzyme and cofactors in 150 µl reaction buffer of 50 mM Tris‐HCl, pH 8.0 
(Asp reactions) or in 25 mM Tris‐HCl, pH 9.0 (Ser reactions) at 30 °C for 2.5 h.  Substrate starting 
concentration of 12 µM L‐Asp, 4 µM D‐Asp, 20 µM L‐Ser or 20 µM L‐Ser was injected into capillary.  
RFU: relative fluorescence units of analyte peaks.  Migration time: time for analytes moving from 
capillary injection site to detection window. Reprinted with permission from reference 41.   
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Figure 3. 6 DAR1 racemase activity characterizations. AOAA inhibition assay (A): 50 mM L‐Asp or 20 
mM L‐Ser was incubated with 1 mM AOAA, 4 µg DAR1 and cofactors in 150 µl of reaction in 25 mM 
Tris‐HCl, pH 8.5 at 30 °C for 2 h.  Reaction concentration of 100 µM L‐Asp or 40 µM L‐Ser was injected 
into CE capillary.  Thermo‐stability of DAR1 racemase activity (B):  80 mM L‐Asp or 50 mM L‐Ser was 
incubated with 1 µg DAR1 and cofactors in 100 µl reaction in 50 mM Tris‐HCl, pH 8.5 at 14°C, 30 °C, 
37 °C, 45 °C or 50 °C for 3 h (Asp) or 1 h (Ser). Reaction concentration of 100 µM (L‐Ser) or 160 µM (L‐
Asp) was injected into capillary. Tris‐HCl with pH7.0 (a, e), 7.5 (b,f), 8.0 (c,g) or 8.5(d, h) at 30°C for 3 
h. Reaction concentration of 1.77 µM L‐Ser or 17.7 uM L‐Asp was injected into capillary.  Reprinted 
with permission from reference 41.   
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Figure 3.6 (cont.) Effects of ATP and MgCl2 on DAR1 racemase activities. L‐Ser (20 mM) or L‐Asp (200 
mM) was incubated with 2 µg DAR1, PLP and DTT and either 4 mM ATP or 2 mM MgCl2 or both in a 
100 µl reaction in 50 mM Tris‐HCl, pH 8.5 at 30 °C for 1 h. Reaction concentration of 40 µM L‐Ser or 
100 µM L‐Asp was injected into capillary. The data were adjusted by controls with heat‐inactivated 
enzyme. Reprinted with permission from reference 41.   
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Figure 3.6 (cont.) pH‐dependency of DAR1 racemase activity:CE‐LIF electrophoregrams of DAR1 
racemase reactions with L‐Asp substrate (A) at pH 7.0 (a), pH 7.5(b), pH 8.0(c), and pH 8.5 (d); or with 
L‐Ser substrate (B) at pH 7.0 (e), pH 7.5(f), pH 8.0 (g), pH 8.5 (h). L‐Ser (13.3 mM) or L‐Asp (26.7 mM) 
was incubated with 1 µg DAR1 and cofactors in 150 µl reaction in 50 mM Tris‐HCl with various pH at 
30 °C for 2.5 h. Reprinted with permission from reference 41.   
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Figure 3.7 Lineweaver‐Burk plots of DAR1 racemase kinetics. Racemase assay with various 
concentrations of Asp or Ser substrates were performed and conversion products were quantified as 
described in the Materials and Methods.  Inverse reaction velocities were plotted against 
corresponding inverse substrate concentrations and fitted as linear curves with Excel to produce the 
Lineweaver‐Burk plots for Asp (a) and Ser (b) substrates. Reprinted with permission from reference 
41.   
78 
 
 Figure 3.8 DAR1‐like immunoreactivity localization in the Aplysia CNS. Whole‐mount staining of the 
CNS (except abdominal ganglia) with rabbit anti DAR1 serum shown as a rhodamine fluorescence 
micrograph (a); BG: (buccal ganglia); CG (cerebral ganglia); PdG: pedal ganglia; PlG: pleural ganglia.  
Light micrograph of desheathed CG control without staining (b); enlarged CG image from (a) showing 
rhodamine fluorescence micrograph (c) and bright‐field fluorescence micrograph (d). Reprinted with 
permission from reference 41.   
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Figure 3.9 CE‐LIF electropherograms of D‐Asp and D‐Ser in CNS neuronal F/C clusters.  Aplysia 
cerebral ganglion F/C cluster neurons were dissected and subjected to amino acid separation with 
CE‐LIF using optimal buffer for Asp separation (a) and for Ser separation (b). Reprinted with 
permission from reference 41.   
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CHAPTER IV 
DESCRIPTION OF APLYSIA RACEMASE β-ELIMINASE ACTIVITY 
BY COMPARATIVE STUDY OF APLYSIA RACEMASE AND SERINE 
DEHYDRATASE 
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4. 1. Introduction 
D-Ser is an endogenous co-agonist of the NMDA glutamate receptor, modulating receptor 
activity by binding to the glycine-binding site in NR1 subunit of NMDAR (1). The 
neurotransmitter/neuromodulator can affect synaptic plasticity of NMDAR (2). Aberrant D-
Ser metabolism has been linked to some neurodegenerative disorders for example, 
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amyotrophic lateral sclerosis (3) and schizophrenia (4). D-Ser is synthesized from L-Ser by 
SR in mammalian neurons and glia (1). Knowledge of serine racemase structure and function 
is important to understand D-Ser biosynthesis and regulation, and more importantly D-Ser 
signaling pathways in vivo.    
 
Eukaryotic SR (EC 5.1.1.18) and aspartate racemase (DR, EC 5.1.1.13) belong to pyridoxal-
5’-phosphate (PLP)-dependent enzyme fold-type II (5) and they are structurally similar to E. 
coli threonine dehydratase (EC 4.3.1.19) (6). To date, only four animal SR have been 
characterized including rat, mouse and human SR (1, 7, 8) and DAR1 from Aplysia 
californica (9). Serine racemase converts between Ser enantiomers in an ATP-Mg dependent 
manner and tend to favor L-Ser over D-Ser substrate.  
 
Besides racemase activity, eukaryotic serine and aspartate racemases display L-Ser 
dehydratase activity (SDH, EC 4.3.1.17) via β-elimination mechanisms (10-12). SDH 
degrades L-Ser to pyruvate and ammonia by a tow-step reaction. The first step is enzymatic 
and PLP-dependent, leading to the elimination of β-hydroxyl group from serine to form 
aminoacrylate intermediate which undergoes rapid nonenzymatic hydrolysis to produce 
pyruvate and ammonia. The terms β-eliminase and dehydratase have been used 
interchangeably in past literature. L-Ser racemization and dehydratization occurs at the same 
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catalytic site of the mouse serine racemase (13) The catalysis steps for both reactions have 
been clearly depicted by Foltyn et al.  (14). An L-Ser substrate bound to a SR can either 
become D-Ser by racemization or lead to pyruvate and ammonia by dehydratization. While 
the racemization reaction is reversible, β-elimination is unidirectional.  
 
The apparent competition between two activities for the same L-Ser substrate by a SR is 
puzzling.  Furthermore, that the faster dehydratase activity and slower racemase activity 
usually observed with eukaryotic SR has raised questions about which activity plays a 
physiological role or under which conditions the racemization activity is physiologically 
important.   
 
As the enzyme products D-Ser (or D-Asp) have well characterized biological activities (15-
18), the physiological function of β-elimination of these racemases is under debate.  There are 
at least three hypotheses to explain the β-elimination activity of the serine racemases.  One 
hypothesis suggests that β-eliminase activity serves as a link between D-Ser transmitter 
production and neuron energy metabolism(19). This explains the dilemma of co-production of 
D-Ser and pyruvate from L-Ser from a SR; this hypothesis fits when considering that ATP is 
required for serine racemase activation (9, 10), and D-Ser transmission, and that subsequent 
cell activation consumes more energy than the resting state. However, it is not clear how 
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much and how quickly the β-eliminase activity of a racemase can contribute to the change of 
a cellular energy level. An unresolved question is why some racemase also dehydratizes L-
Thr that forms 2-oxobutanoate, a compound does not contribute to energy metabolism 
(http://www.genome.jp/kegg/pathway.html). A second hypothesis proposes that serine 
racemase can serve as a metabolic enzyme to degrade D-Ser in mammalian forebrain where 
D-amino acid oxidase is absent (14). The most recent hypothesis agrees that β-elimination 
limits D-Ser levels by degrading D-Ser and its precursor L-Ser but also provides a “serine 
shuttle” model to explain how a neuron can solve the dilemma of D-Ser being made and 
destroyed at the same time (20). But D-Ser degradation models do not explain why bivalve 
aspartate racemase also has an L-Ser dehydratase activity (12), and perhaps more importantly, 
why a serine racemase limits an already slow serine racemase activity by degrading its 
product D-Ser and precursor L-Ser, especially as other enzymes exist that have dehydratase 
activity alone.  
 
We have recently described the first invertebrate serine racemase DAR1 from Aplysia 
californica CNS (9), with this enzyme also having significant Asp racemase activity. As 
shown below, the enzyme shares many protein and enzyme features with mammalian serine 
racemases and has a specific L-Ser dehydratase activity. Because the localization and activity 
of specific Aplysia neurons can be studied, enzyme function can be linked to higher order 
network functions. DAR1 appears an enzyme well suited to studying the β-elimination 
activity of eukaryotic racemase to address issues of its physiological functions. During the 
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search for serine/aspartate racemase in Aplysia, we also located a putative serine dehydratase 
gene acsdh in an Aplysia CNS EST library. The gene is expressed in the Aplysia cerebral 
ganglion where DAR1 is located. Enzyme assay with recombinant AcSDH protein confirmed 
that it is an L-Ser dehydratase with weaker L-Threonine (L-Thr) dehydratase activity but no 
racemase activity.  AcSDH has hence provided us with an enzyme to compare the function 
and localization of the L-Ser dehydratase activity of DAR1. We compared the two Aplysia 
protein sequences, their L-Ser dehydratase activities under different conditions and enzyme 
kinetics. Our results show that AcSDH is a robust L-Ser dehydratase whereas DAR1 L-Ser 
dehydratase activity is reduced compared to AcSDH, suggesting that the racemase activity is 
more significant than the creation  
 
4.2. Materials and Methods 
4.2.1 ORF Cloning of acsdh cDNA 
Restriction enzymes were purchased from NEB (Ipswich, MA) and other cloning reagents 
were purchased from Invitrogen (Carlsbad, CA); enzyme reaction cleaning kits and miniprep 
reagents were purchased from QIAGEN. The dar1 cDNA cloning from Aplysia CNS RNA 
was described by Wang, et al. (9). The cDNA of acsdh was initially cloned from Aplysia CNS 
EST library of juvenile Aplysia by Dr. Moroz at University of Florida and given us as an ORF 
fragment in pCR®2.0-TOPO® vector in a bacterial stock. But the ORF of acsdh cDNA was 
re-cloned by RT-PCR for expression vector cloning using forward PCR primer: 5’-
GGCTCGAGATGGATTCCAAACCAGAT-3’ (the XhoI site underlined) and reverse primer 
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5’-CCTGATCATATGCCAAAGTCTGCCTT-3’ (the BclI site underlined) and pfuTurbo 
DNA polymerase (Agilent Technologies) with 55 °C annealing temperature. The PCR 
product was cloned into PCR®4-TOPO® vector and transformed into TOP10 cells and 
sequenced. Final clone used for expression vector construction was named 418M.   
 
4.2.2 Protein Expression and Purification 
Bacterial expression vector pET-15b, BL21(DE3) competent cells, NiNTA resin, protease 
cocktail, BugMaster Mix bacterial lysis buffer were purchased from EMD4Biosciences 
(Gibbstown, NJ). HiPrep Sepharcryl 200 HR 16/60 sizing column and low molecular weight 
standard kit for gel filtration were bought from GE Healthcare Life Sciences (Piscataway, NJ). 
The acsdh expression vector was constructed by digesting 418M plasmid with XhoI and BclI 
restriction enzymes and cloned the XhoI and BclI fragment between XhoI and BamHI sites of 
pET-15b. The resulting vector was transformed into TOPO 10 cells, sequenced and then 
transformed into E. coli BL21 (DE3) protein expression cells. AcSDH expression and 
purification were carried out by following the same procedures as those for DAR1 as reported 
by us before (9).   
 
4.2.3 Protein Homology Analysis 
The protein sequences of 13 PLP-dependent enzymes were downloaded 
from http://www.ncbi.nlm.nih.gov website. Bioinformatics analysis was conducted at SDSC 
Biology Workbench website: http://workbench.sdsc.edu/. DAR1 and AcSDH sequence were 
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aligned with ALING program; multiple protein sequence alignments were performed with 
ClustalW program and outputted as rooted phylogenetic dendrogram or inferring evolutionary 
tree by Phylip’s Drawgram.  
 
4.2.4 Racemase Assay  
All chemicals are highest grades and purchased from SIGMA-Aldrich (St. Louis, MO) unless 
specified otherwise.  DAR1 assay: 1 μg DAR1 (1 μg/μl) was added to 149 μl substrate mix 
containing 10 mM L-Ser in buffer mix containing 50 mM Tris-HCl with pH 7.0-10.0, 15 μl 
PLP, 2 mM DTT and MgCl2 and 4 mM ATP at 30 °C for 2.5 h.  The reactions were stopped 
by adding 5 % Trichloroacetic acid (TCA), and then 5 mM glycine was added to each sample 
for internal control of subsequent amino acid analysis by capillary electrophoresis laser 
induced fluorescence detection (CE-LIF).  After 15 min on ice, the samples were centrifuged 
at 10,000 x g to remove protein precipitates, and the supernatants were extracted with an 
equal volume of water-saturated ether 2 times to remove TCA. The samples were then diluted 
1:10 with 50 mM borate, pH 9.4, and 2 μl of the diluted samples were derivatized with 4 μl of 
8 mM naphthalene-2,3-dicarboxaldehyde (NDA, Invitrogen) and 4 μl of 40 mM potassium 
cyanide (KCN) at RT for 60 min. The reaction was stopped by diluting the samples with 50 
mM borate pH 8.5, and the samples were immediately frozen on dry ice and subjected to CE-
LIF analysis within 24 h as described by Wang et al. (9). AcSDH assay: 1 μg of AcSDH (1 
μg/μl) was added to a substrate mix containing one of the four amino acids (L-Ser, L-Asp, L-
Ala, L-Glu) at 20 mM and 100 mM concentrations in a total 100 μl of reaction containing 50 
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mM Tris, pH 8.5, 20 μM PLP and 2 mM DTT at 30 °C for 2.5 h. Negative controls contained 
no enzyme. Post-incubation treatment and NDA derivatization procedures were the same as 
for DAR1 racemase assay described above. The CE-LIF analysis of racemase products of D-
Ser, D-Asp, D-Ala or D-Glu was described by Wang et at. (9). 
 
4.2.5 β-eliminase Assay 
All chemicals for assay were of highest purity and purchased from Sigma-Aldrich (St. Louis, 
MO), unless specified otherwise.  L-(-)-threo-3-hydroxyaspartic acid (LT3HA) was purchased 
from TOCRIS Biosciences (Bristol, UK); L-Ser-O-sulfate (LSOS) and amino-oxyacetate 
(AOAA) were purchased from SIGMA-Aldrich. Serine or threonine dehydratase converts 
serine or threonine or their derivatives to keto acids and ammonia by β-elimination (13). The 
dehydratase activity can be measured by detecting α-keto acid products with 2, 4-
dinitrophenylhydrazine (DNPH) in a colorimetric assay as described by Abe et al. (12) which 
was used with some modifications. An enzyme reaction started by adding 1 μl (0.25-1μg) of 
an enzyme to a substrate mixture of 99 μl, containing a substrate, cofactor PLP (15 µM) and 
DTT (2-5 mM) for AcSDH assay, and in addition, MgCl2 (2 mM) and ATP (1 mM) for 
DAR1 assay in 50 mM Tris-HCl, pH 8.5 buffer (unless specified otherwise). Except for 
temperature assays, all other assays were carried out at 30 °C. Enzyme reactions were 
incubated for 60 min and then stopped by adding 25 μl of 25 % TCA. Negative controls 
contained no substrates.  Every assay was repeated with three batches of enzyme preparations 
and technically triplicated. After TCA termination, color detection of keto acid was performed 
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by incubating samples with 70 µl of 0.1% DNPH in 2 N HCl at 30 °C for 15 min, followed by 
the addition of 500 µl of 3.75 M NaOH and incubation at 37 °C for 15 min. Finally, the 
samples were centrifuged at 8,800 x g for 10 min at RT, and 200 µl of supernatants were 
measured at O.D. 445 nm for the absorption of 2, 4-dinitrophenyldydrazone in 96-well flat 
bottom microtiter plates (Thermo Fisher Scientific) with Spectramax Plus 384 
spectrophotometer by Molecular Devices (Sunnyvale, CA). The O.D. 445 nm values were 
adjusted with negative controls and presented as Y-axis of values in graphs. The mean of 
three replicates and standard deviations are displayed.    
 
4.2.6 Kinetics Assay of β-elimination Reaction 
Optimal assay conditions tested were used to measure kinetics. For DAR1 assay, 1 μl of 
DAR1 (500 ng/μl) was added to a 99 μl reaction mix containing L-ser (2.5-80 mM), 15 μM 
PLP, 2 mM DTT and MgCl2, and 4 mM ATP in 50 mM Tris-HCl, pH 8.5 buffer and 
incubated at 30 °C (except for temperature assay) for 60 min. Reactions without substrate 
were blank controls. For AcSDH assay, 0.3 μg of AcSDH (for L-Ser reactions) or 0.5 ug of 
AcSDH (for L-Thr reactions) was added to a reaction mix containing either L-Ser or L-Thr, 
15 μM PLP and 5 mM DTT in 25 mM Tris-HCl, pH 9.0. The amount of enzyme was adjusted 
so that the pyruvate produced from the highest substrate concentration reactions were within 
the linear range of 0.05- 1.6 mM. Pyruvate standard series (0, 0.05, 0.1, 0.2, 0.4, 0.8, 1.6 mM) 
were co-incubated separately with enzyme samples in the enzyme assay buffer (without 
substrate) to produce a standard linear curve (O.D. 445 nm values versus pyruvate 
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concentrations). The linear equation of the standard curve was used to measure the pyruvate 
quantity produced by an enzyme reaction. Enzyme specific activity was defined as μmoles of 
pyruvate produced by 1 mg of enzyme during one hour incubation at 30 °C. Specific activities 
were plotted against substrate concentrations and the resulting curves were fitted with non-
linear regression Michaelis-Menten model with OriginPro8 software (OriginLab, 
Northampton, MA) to produce Km and Vmax.  The Km and Vmax from three enzyme batch 
repeats were averaged and presented with standard deviation in kinetics table.  
 
4.3 Results 
4.3.1 Protein Expression and Purification  
SDS-PAGE analysis results of protein expression and purification are shown in Fig. 4.1.  
DAR1 and AcSDH recombinant proteins were both over-expressed in E. coli with IPTG 
induction.  The proteins were purified from bacterial cells to homogeneity through nickel 
NTA affinity and gel filtration chromatography as described by Wang et al. (9). The 
recombinant proteins showed electrophoresis mobility of about 37.0 kDa as predicted.  
Molecular size calibration with gel filtration column indicated that both proteins formed 
dimmers in solutions (data not shown).  Purified protein preparations appeared yellow-green, 
suggesting the association of protein molecules with bacterial endogenous PLP cofactor.   
 
4.3.2 Protein Homology Analysis 
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Figure 4.2 shows DAR1 (325 aa) and AcSDH (332 aa) predicted protein sequences and their 
optimal global alignment.  The two proteins share 27 % homology including a conserved 
PLP-attachment motif surrounding putative PLP-interacting Lys56 (DAR1) or Lys50 
(AcSDH) (12). Fifteen PLP-dependent enzyme sequences were aligned and alignment output 
was displayed a rooted phylogenetic tree shown in Fig. 4.3.  The tree indicates that DAR1 is 
closest to bivalve DR and five eukaryotic serine and aspartate racemases form a family. 
AcSDH belongs to serine dehydratase family (SDH).  Mouse aspartate racemase belongs to 
amino transaminase family.  The three families are related to each other and to E. coli 
threonine dehydratase, biosynthetic and catabolic.   
 
4.3.3 β-elimination Substrates and Competitors 
Eleven amino acids were examined as substrates of DAR1 and AcSDH β-elimination activity.  
As predicted, only amino acids with hydroxyl functional groups were the substrates of β-
elimination as shown in Fig. 4.4a.  Both enzymes showed activity towards L-Ser but AcSDH 
activity is much stronger than DAR1; AcSDH also has a weaker activity towards L-Thr. As 
shown in Fig 4.4b, the two enzymes also have activity on L-serine-O-sulfate (LSOS), an L-
Ser derivative; DAR1 also is very active towards LT3HA, an L-Thr/L-Asp derivative.  DAR1 
activity was 3 times and 50 times more active on LSOS and LT3HA than L-Ser, respectively.  
AcSDH showed a comparable activity on LSOS and L-Ser.  
 
4.3.4. Enzyme β-elimination Activity Characterization 
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DAR1 and AcSDH L-Ser dehydratase activities were examined for PLP-dependency, thermo-
stability, and the influence by reaction buffer pH and ion strength.  Both enzymes were 
inhibited by AOAA, a competitor of PLP as shown in Fig 4.5a.  The enzymes have a similar 
thermo-stability profile as shown in Fig. 4.5b. Activity increased as temperature went from 
14 °C to 37 °C, but AcSDH lost activity at 45 °C and DAR1 stayed more active at 45 °C and 
only lost some activity at 50 °C, meaning AcSDH is more sensitive to higher temperature than 
DAR1.  DAR1 and AcSDH showed different response to pH and buffer strength change, as 
demonstrated in Fig. 4.5c and Fig 4.5d, respectively.  DAR1 displayed a pH-response pattern 
independent of Tris-HCl concentrations: sharp increase from pH7.0 to 7.5, slightly decreasing 
activity at pH 8.0, increasing activity at pH 8.5 and leveled or decreasing activity at pH 9.0.  
The enzyme also showed more activity in higher Tris-HCl concentration with an order of 100 
mM > 50 mM > 25 mM.  In contrast, AcSDH activity is clearly alkaline dependent and also 
favors lower Tris-HCl concentrations.  Divalent cation (2 mM) and nucleotide (1 mM) effects 
had different effects on DAR1 and AcSDH.  Fig 4.6a shows that MgCl2 and CaCl2 promoted 
DAR1 activity, ZnCl2 and CuCl2 inhibited it, and MnCl2 had no effect on it; Fig 4.6b 
demonstrated that MgCl2 had no effect on AcSDH activity; CaCl2 was slightly stimulating it 
and MnCl2, ZnCl2 and CuCl2 inhibited it.  Fig 4.6c showed that ATP, ADP and GTP strongly 
promoted DAR1 activity, and AMP and GDP also promote DAR1 activity but to a much less 
extent.  In contrary, all adenosine and guanosine nucleotides had more or less inhibition 
effects on AcSDH with strongest inhibition effects observed with ATP, ADP and GTP as 
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demonstrated in Fig. 4.6d.  At 4 mM nucleotide concentrations, the inhibition effects to 
AcSDH were stronger (data not shown).   
 
4.3.5 Alkaline Dependence of D-Ser Production by DAR1 
DAR1 L-Ser racemase activity showed increased size of D-Ser peaks as assay buffer 50 mM 
Tris-HCl went from pH7.0-10.0 as shown in CE-LIF electrophoregrams (Fig.4.7a) or as 
normalized D-Ser peak values in 25 mM, 50 mM and 100 mM Tris-HCl buffers with pH7.0-
9.5 with 0.5 pH unit increment in the line graph as in Fig 4.7b. As shown in the line graph, D-
Ser production continued to increase between pH9.0-9.5 for 50 mM and 100 mM Tris buffers 
while 25 mM buffer gave a peak value at pH9.0. Among three buffers tested, 50 mM Tris-
HCl buffer showed a stable and consistent better performance than that in 25 mM and 100 
mM Tris-HCl buffers.   
 
4.3.6 Enzyme Kinetics Parameters 
Fig. 8a demonstrated a linear relationship between the concentration series of standard sodium 
pyruvate (0-1.6 mM) and corresponding O.D. 445 nm values obtained from the color assay 
described in the Material and Methods.  The standard curve was used to calculate dehydratase 
activity reaction products α-keto acids.  The representative substrate saturation curves of 
DAR1 reaction with L-Ser substrate (Fig 4.8b), or AcSDH reaction with L-Ser (Fig 4.8c) or 
L-Thr (Fig. 4.8d) substrates were shown with overlaying Michaelis-Menten non-linear 
regression fittings.  Table I shows the kinetics parameters of L-Ser racemase and L-Ser 
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dehydratase reaction catalyzed by DAR1, and L-Ser and L-Thr dehydratase reactions 
catalyzed by AcSDH under the experimental conditions used.  L-Ser dehydratase activity is 
3.5 times faster than L-Ser racemase activity when determined by enzyme turnover number 
kcat.  For AcSDH, L-Ser dehydratase activity is 7 times faster than L-Thr dehydratase activity.  
When L-Ser dehydratase activity was compared, AcSDH was 20 times faster than DAR1. 
Finally, the catalytic efficiency (kcat/Km) of AcSDH on L-Ser dehydratization is 7 times higher 
DAR1.    
 
4.4 Discussion 
The two Aplysia enzymes, DAR1 and AcSDH are functionally related but how close are they 
to each other and to other PLP—dependent enzymes?  Protein homology analysis by multiple 
sequence alignment of 15 PLP-dependent enzymes separated DAR1 and AcSDH to two 
different families as shown in the inferring evolutionary tree as shown in Fig. 4.3. DAR1 
belonged to racemase family which members include bivalve DR (EC 5.1.1.13) and 
mammalian SR (EC 5.1.1.18) while AcSDH was grouped with eukaryotic serine dehydratase 
(EC 4.3.1.17, E) and threonine dehydratse (EC. 4.3.1.19), or simply named serine dehydratase 
(SDH) family. Mouse DR represents a distinct eukaryotic racemase which belongs to 
aspartate transaminase (EC 2.6.1.1) family and is not discussed further. The racemase and 
SDH families, and E. coli threonine dehydratase (THD, EC 4.3.1.19), both biosynthetic and 
catabolic enzymes (EC 4.3.1.19) seemed to be closely related but evolved divergently from a 
common distant ancestor. They share a structural similarity of fold type II within PLP-
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dependent enzymes and the same catalytic function as β-eliminases. It is possible that the 
distant ancestor was a prokaryotic serine or threonine dehydratase which passed its β-
eliminase activity to the racemase and SDH families. In bacteria, serine and threonine 
dehydratases are usually two separate enzymes but the eukaryotic SDH family members have 
both serine and threonine dehydratase activities. It is likely, therefore, the ancestor added one 
more β-elimination substrate to become today’s dual-substrate dehydratase while racemase 
family acquired racemase function and evolved into the today’s racemase enzyme. Although 
both families possess L-Ser dehydratase, they are probably to be selected by nature to serve 
different physiological functions: SDH family to make keto acids from L-Ser and L-Thr, and 
the racemase family to synthesize D-Ser or D-Asp.       
 
DAR1 and AcSDH demonstrated different substrate profiles. Both enzymes can dehydrataze 
L-Ser but DAR1 is inactive to L-Thr while AcSDH has a moderate L-Thr activity. DAR1 is 
thus different from mouse SR which substrates include L-Ser, D-Ser and L-Thr (14). More 
importantly, DAR1 has Ser and Asp racemase activities (9) but AcSDH had no detectable 
racemase activity towards L-Ser, L-Asp, L-Ala and L-Glu substrates under the same assay 
conditions as its L-Ser dehydratase assay confirming that this is a SDH and not a racemase.  
We also examined two chemical compounds LSOS, an L-Ser derivative, and LT3HA, an L-
Asp derivative with a hydroxyl group as enzyme dehydratase substrates. The compounds are 
strong substrates of mouse racemase β-elimination activity (9, 12, 14) and they could non-
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competitively inhibit mouse SR racemase activity (13).  DAR1 showed stronger activity 
towards both compounds than L-Ser, a result also observed with mouse SR with LSOS (21) or 
that with bivalve DR with LT3HA (12). Differently, AcSDH only had activity towards LSOS 
with a comparable level to L-Ser substrate. The different substrate profile suggests that DAR1 
and AcSDH have different catalytic binding pockets. LT3HA occurs in some polypeptide 
antibiotics which are blockers of excitatory amino acid transporters (22). But we haven’t 
found any literature showing both compounds are endogenous in animals. 
 
Determining the conditions of activity are important indicators to enzyme functions. Both 
DAR1 and AcSDH β-elimination activities were inhibited by amino-oxyacetic acid (AOAA) 
DAR1 and AcSDH L-Ser dehydratase activity favor different reaction conditions. In 25 mM, 
50 mM and 100 mM Tris-HCl buffers, DAR1 demonstrated pH-dependent activity with a 
sharp increase from pH7.0 to pH 7.5 and a complex activity profile between pH 7.9-9.0 (Fig. 
4.5c). In addition, for any given pH DAR1 was more active in high ionic strength than lower 
ionic strength buffers. Of course, Aplysia cells contain a high ionic strength (>500 mM 
cationic concentration in their cytoplasm). Quite distinct, AcSDH is clearly alkaline 
dependent showing continued increasing activity from pH7.0-9.0 for the tested three ionic 
strength buffers (Fig. 4.5d); and the enzyme was more active in lower ionic buffer, opposite 
to DAR1. The different ionic preferences suggest that the two enzymes might achieve their 
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optimal activities in separate subcellular compartments in a cell or under different 
physiological conditions. More cellular/molecular physiology work is needed to confirm this.   
 
Eukaryotic racemase activity dependence on divalent cations and nucleotides is well 
documented (9, 10, 12). In this study, we examined these effectors on L-Ser dehydratase 
activity of DAR1 and AcSDH. We have examined five divalent cations and eight nucleotides 
that are frequent enzyme stimulation or inhibition effectors. The two enzymes showed distinct 
reactions to Mg2+, Ca2+ and Mn2+ and have the opposite reactions to ATP, ADP and GTP. The 
different reactions to the effectors suggest that the enzymes are activated by different 
metabolic conditions thus they likely have different physiological functions. For example, 
AcSDH plays an important role in pyruvate metabolism which can lead to energy production 
thus the enzyme can be feedback inhibited by energy molecules ATP, ADP and GTP; DAR1is 
probably involved in a cellular process that requires a sufficient cellular energy level to be 
activated, for example, neuronal excitation or signal transduction activation.  
 
We measured Km and Vmax of DAR1 and AcSDH and calculated parameter kcat and kcat/Km for 
both enzymes. Based on the kcat, DAR1 was 3.5 fold faster in generating pyruvate from L-Ser 
than producing D-Ser from L-Ser under the experimental conditions used. The faster L-Ser β-
elimination reaction than L-Ser racemase reactions was also observed with mouse SR (10). 
The two enzymes showed a great difference in catalyzing L-Ser to pyruvate and ammonia per 
unit time: AcSDH was 20-fold faster than DAR1. In addition, AcSDH kcat/Km is also at least 7 
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times larger than DAR1. Both kinetic parameters strong indicate that AcSDH functions as β-
eliminase with a robust L-Ser dehydratase activity while DAR1 L-Ser dehydratase activity is 
weaker, lending credence to the importance of its other cellular function.  
 
The DAR1 dehydratase activity pH profile (Fig. 4.5c) showed that its pyruvate production 
rate had a complex pH dependence profile as the buffer pH increased from neutral to basic 
and DAR1 racemase pH-dependent profile showed a gradual upward trend as pH went from 
7.0 -10.0 with 0.5 pH increments as shown in CE-electrophoregrams Fig. 4.7a or the line 
graphs in Fig. 4.7b. In parallel, mouse SR L-Ser dehydratase reached peak activity at pH 8.0 
but its L-Ser racemase activity did not reach peak value until pH 9.0 (21). The different 
responses to alkaline pH by the two activities of a serine racemase are interesting. Mammalian 
cytosolic pH is 7.0-7.4 (23) but at this pH range, mouse SR racemase activity was only 30% 
of its peak activity at pH 9.0 (21). Molluscan intracellular pH is similar 7.2 (24). But at pH 7.0 
with 50 mM Tris-HCl buffer, D-Ser production by DAR1 was only 21% of that at pH 10.0 
(with CE internal control normalized value shown in Fig 4.7b). Therefore, to achieve faster 
conversion, the racemase should be located in an cellular compartment with a basic milieu, or 
should such a basic environment be absent, a racemase might raise the local pH of the 
surrounding enzyme catalytic pocket by creating ammonia from Ser/Thr breakdown by its β-
elimination activity. Therefore, one function of the β-elimination is not directly involve 
energy metabolism but produces ammonia from Ser and/or Thr substrates. This hypothesis 
can explain why two apparent completing reactions coexist in a racemase; the β-elimination 
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activity is probably not to complete with racemase activity for L-Ser substrate to make 
pyruvate or breakdown D-Ser to prevent neurotoxicity, rather to assist racemase activity to 
achieve its maximum activity by creating an alkaline environment by producing ammonia.  
 
In addition, both bivalve and DAR1 aspartate racemase activities are also promoted under 
alkaline conditions and both enzymes have L-Ser dehydratase activities (9, 12). Second, 
mouse SR β-elimination substrates include L-Ser, D-Ser and L-Thr. Ser and Thr breakdown 
involve the formation of pyruvate and 2-oxobutanoate, respectively, plus ammonia. Pyruvate 
can be an energy source via the citric acid cycle but 2-oxobutanat enters a non-energy related 
metabolic pathway (http://www.genome.jp/kegg/pathway.html). Given these reasons, we 
expect that energy and/or controlling D-Ser levels may not be primary function of β-
elimination activity of a serine racemase. Does the generation of ammonia used to enhance 
racemase activity? Further studies are needed with other eukaryotic serine racemases to 
support this hypothesis.   
 
4.5 Conclusions 
Like other eukaryotic serine or aspartate racemases, DAR1 also has L-Ser racemase and L-Ser 
dehydratase activities. The former activity produces D-Ser from L-Ser and the later degrades 
L-Ser to pyruvate and ammonia. While D-Ser physiological functions in animals are well 
documented, it is not clear what the physiological function of the L-Ser dehydratase activity is. 
To address the issue, a comparative study with DAR1 and Aplysia L-Ser dehydratase AcSDH 
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were conducted. Both enzymes were in Aplysia CNS and both have L-Ser dehydratase 
activities. Protein homology analysis, enzyme characterizations under different conditions and 
enzyme kinetics studies have revealed that they belong to eukaryotic racemase family and L-
Ser dehydratase family, separately. Their L-Ser dehydratase activities showed distinct 
behaviors at alkaline pH conditions, favored low or high buffer strengths and responded to 
Ca2+, Mg2+ or Mn2+ effectors differently. They also reacted to nucleotide ATP, ADP and GTP 
in an opposite manner. The different characters displayed by the two enzymes have strongly 
suggested their different physiological functions. Enzyme kinetic parameter analysis 
demonstrated that AcSDH has 20 folds larger kcat and 7 folds larger kcat/km than DAR1. 
Together, the data strongly suggest that AcSDH plays a role in keto acid metabolism and/or 
energy metabolisms by producing pyruvate from L-Ser by its robust L-Ser dehydratase 
activity and 2-oxobutanoate from L-Thr by its moderate L-Thr dehydratase activity. DAR1 
showed a much weaker L-Ser dehydratase activity compared to that of AcSDH, thus it might 
serve different cellular functions other than pyruvate metabolism. Since DAR1 L-Ser 
racemase is alkaline dependent, its L-Ser dehydratase activity can create an alkaline 
environment for its racemase activity by producing ammonia. Therefore, the physiological 
function of DAR1 β-eliminase activity is probably not to compete with its racemase activity 
rather to assist it. The pH hypothesis needs more studies with other serine and aspartate 
racemases to prove. 
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4.6 Figures 
 
 
 
 
 
 
 
 
 
Figure 4.1 Protein expression and purification. Bacterial lysates prepared from protein expression 
host cells and purified proteins were subjected to SDS‐PAGE with 4‐20% PreciseTM protein gel under 
reducing conditions. The Coomassie blue staining of the gel: 5 µl Precision Plus ProteinTM Standards 
(lane 1); 5 µl lysates from non‐induced and IPTG induced AcSDH culture (lane 2 and 3) or DAR1 (lane 
5 and 6) samples; 1 µg of purified recombinant AcSDH (lane 4) or DAR1 (lane 7).    
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Figure 4.2 DAR1 and AcSDH protein sequence alignment. Two protein sequence alignment was 
carried as described in the Material and Methods.  Asterisk: identical amino acids; colon: conserved 
amino acids; period: similar amino acids; underlined: putative PLP‐binding motif; red colored K: 
putative PLP binding lysine. Sequence homology: 27 %. 
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 Figure 4.3 Inferring phylogenetic tree of 15 PLP‐dependent enzymes. The rooted phylogenetic tree 
was generated as described in the Materials and Methods. TDH: threonine dehydratase; SDH: serine 
dehydratase; AST: aspartate aminotransferase; SR: serine racemase; DR: aspartate racemase; mouse 
SDH(NP_663540); rat SDH(NP_446414); human SDH(NP_006834); 
AcSDH(A. californica serine dehydratase: gb_AAU05774.1); yeast SDH (gb_AAA35040.1); human 
AST(NP_002070); mouse DR (25); E. coli biosynthetic TDH (NP_418220); E. coli catabolic TDH 
(AP_003665); DAR1(A. californica D‐amino acid racemase 1, AC_HM776055); bivalve DR(BAE78
rat SR(NP_942052); mouse SR(NP_001156783
960.1); 
); human SR(NP_068766).  
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Figure 4.4 Dehydratase activity substrates and competitors. Eleven amino acids (10 mM) and L‐Ser 
derivative, LSOS (10 mM) and L‐Asp derivative, LT3HA (1 mM) were co‐assayed with 500 ng of DAR1 
or AcSDH in dehydratase assay as described in the Materials and Methods.  Amino acid substrates 
results are shown in (a) and comparative results of L‐Ser/L‐Thr versus LSOS and LT3HA were shown in 
(b).  
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Figure 4.5 Enzyme characterizations.  Inhibition of PLP‐dependent SDH activity by AOAA (4a): L‐Ser 
(10 mM) was incubated with 500 ng of enzyme in the presence of 1 mM AOAA in reaction buffers.  
Thermo‐stability profiles of SD activity (4b): L‐Ser (50 mM) was incubated with 250 ng AcSDH or 1 µg 
DAR1 at 14 °C, 30 °C, 37 °C, 45 °C and 50 °C.  Ion strength and pH effects on SD activity of DAR1 (4c) 
and AcSDH (4d): L‐Ser (10 mM) was incubated with 1 µg DAR1 or 0.5 µg AcSDH in 25 mM, 50 mM, or 
100 mM Tris‐HCl buffers with pH 7.0, 7.5, 8.0, 8.5 or 9.0.   
 
 
 
 
 
 
 
109 
 
 
 
 
 
 
 
 
 
Figure 4.6 Cation and nucleotide effects on enzyme activity. Divalent cation assay: metal chloride salt 
(2mM) was incubated with 10 mM L‐Ser and 1 µg DAR1 (5a) or 0.5 µg AcSDH (5b) in 50 mM Tris‐HCl, 
pH 8.5 containing15 µM PLP and 2 mM DTT buffer. DAR1 assay also included 1 mM ATP. Y‐axis: 
relative activity (O.D. 445 nm values were adjusted with no cation values). Nucleotide assay: 
adenosine and guanosine nucleotide was incubated with 40 mM L‐Ser and 400 ng of DAR1 (5c) or 
AcSDH (5d) in the Tris‐HCl buffer mix above. DAR1 reactions also included 2 mM MgCl2. The O.D. 445 
nm values were adjusted with no enzyme controls.  
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Figure 4.7 Alkaline pH‐dependence of DAR1 D‐Ser production. Results shown as electrophoregrams 
(A) or shown as normalized D‐Ser peak values (B).  L‐Ser racemase assay and CE‐LIF detection of D‐
Ser products were described in the Materials and Methods in Chapter III, section 3.2.7.  CE‐LIF 
detection results are shown by CE‐electrophoregrams for racemase reactions conducted in 50 mM 
Tris‐HCl, pH 7.0 (a), pH 8.0(b), pH 9.0 (c), and pH 10.0 (d).  Normalized D‐Ser peak area:  D‐Ser peak 
area was divided by glycline peak area in the same CE‐LIF electrophoregram.   
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Figure 4.8 Enzyme β‐elimination kinetics curves. Pyruvate standard curve and linear fitting (6a), 
representative enzyme kinetics curves with Michaelis‐Menten fittings: L‐Ser kinetics by DAR1 (b), L‐
Ser kinetics by AcSDH (c), and L‐Thr kinetics by AcSDH (d).  
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4.7 Table 
 
Table 4.1 DAR1 and AcSDH kinetics parameters 
Enzyme     Reaction             KM (mM)     VMax (µmol mg
‐1 h‐1)        kcat (min
‐1)         kcat/KM (min
‐1 mM‐1) 
DAR1     L‐Ser           D‐Ser           *14.9 ± 1.84          *11.0 ± 0.61             6.8 ± 0.2            0.56 ± 0.1 
     L‐Ser           pyruvate            15.28 ± 1.2            80.8 ± 6.32             25.18 ± 1.95             1.65 ± 1.6 
 
AcSDH        L‐Ser           pyruvate            13.16 ± 1.9            326.4 ± 32.4                  619.6 ± 61.5  47.08 ± 32.4
   
    L‐Thr           2‐oxobutyrate          12.17 ± 0.97             61.6 ± 3.8                  76.69 ± 4.7  6.3 ± 4.8 
 
*Serine racemase reaction KM and VMax were measured and described by (9, 12). The kinetics parameters of β‐
elimination reactions were determined by measuring α‐keto acids (pyruvate or 2‐oxobutanoate) in the color 
assay as described In the Materials and Methods. Recombinant protein molecular weights of 37.3kDa and 
37.6kDa were used to calculate kcat for DAR1 and AcSDH, respectively. One catalytic site per enzyme molecule 
was assumed. Values are means ± SEM, N=3 (data collected with 3 batches of enzyme preparations).  
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5.1 Introduction  
This chapter includes three methods and two experiments and that are not included in the 
previous chapters. The two of the methods are alternative approaches that were used to clone 
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DAR1 5’ UTR and 3’ UTR. The third method was developed for performing DAR1 enzyme 
assay in 96-well plate format. These methods were integrated parts of my research efforts on 
DAR1 project thus necessary to be included in this dissertation. More importantly, these have 
become successful methods so that they can be used as reliable and useful references for 
future students who work on cDNA cloning or D-amino acid study with enzyme approach. 
The last two projects are distinct.  One of the two experiments included in the chapter is to 
develop a monoclonal antibody for detection/characterization of D-amino acid containing 
peptides (DAACPs) in animal tissues. The experiment is an integrated part of D-amino acid 
research efforts in the Sweedler group and thus worth being described in the dissertation. 
Another experiment was a part of a collaboration project on mammalian circadian system 
study with Martha Gillette Laboratory. Although the project was not associated with DAR1 
project, it provided me a necessary opportunity to gain knowledge and hands-on experiences 
on CE-LIF system which was used heavily in DAR1 enzyme assay later. In addition, the data 
derived from the CE-LIF analysis provided useful information for designing following 
experiments on L-glutamate effects on mouse circadian system. The three methods related to 
DAR1 projects are described first and then followed by two experiments, DAACP antibody 
production and CE-LIF analysis of microdialysis fluid samples looking for neurotransmitter 
L-glutamate change in suprachiasmatic nucleus (SCN). 
 
5. 2 Cloning of 5’ UTR with Terminal Deoxynucleotidyl Transferase 
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The 5’ UTR of dar1 cDNA was first cloned using RNA ligase-mediated 5’ RACE method as 
described in the Chapter III, section 3.2.2. The resulting 5’ UTR fragment only consists of 20 
nucleotides and it is unusually short. Thus the 5’ UTR needed to be verified by an alternative 
5’ RACE method. The method was used as the alternative method which was mentioned in 
Chapter III but is described in detail as follows.  
 
To perform terminal deoxynucleotidyl transferase (TdT) ) mediated 5’ RACE, A new batch of 
total RNA was prepared from CNS material from 4 fresh adult animals of 200 grams and 
RNA was extracted by TRIzol reagent as described in Chapter III, 3.2.2. RNA integrity was 
confirmed by Agilent Bioanalyzer before 5’ RACE experiment. The alternative 5’RACE kit 
was purchased from Invitrogen and used by following product instructions.  
 
The first strand cDNA was synthesized with 7.84 μg of total RNA, 2.5 pmoles of GSP primer 
(R952): 5’-GAT TCC CAC CAC ACA AAA TG-3’ and 2 μl (200 units) of Superscript II 
reverse transcriptase in a 54 μl total reaction volume in 250 μl of PCR tubes for 50 min at 
42 °C in a PCR machine. The newly synthesized cDNA was then immediately purified with 
S.N.A.P column and eluted into 50 μl of preheated 65 °C water. A dCTP tail was then added 
to the 3’ end of the first strand cDNA by TdT enzyme. The tailed cDNA was then amplified 
with GSP R350: 5’-CGGATT GCA TTC TTC TTC AC-3’ and commercial primer AAP: 5’-
GGC CAC GCG TCG ACT AGT ACG GGI IGG GII GGG IIG-3’, and native Taq DNA 
polymerase with the following PCR reaction profile: 94 °C for 2 min for 1 cycle, 94 °C for 1 
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min, 55 °C for 30 sec, 72 °C for 2 min for 35 cycles and 72 °C for 10 min. The PCR product 
was re-amplified using nested PCR with GSP R202: 5’-GAC ACT TCA AAA CGG CAT 
TC-3’ and commercial primer AUAP: 5’-GGC CAC GCG TCG ACT AGT AC-3’ and native 
Taq with the following profile: 94 °C for 2 min for 1 cycle; 94 °C for 1 min, 55 °C for 30 sec, 
72 °C for 1 min for 29 cycles; 72 °C for 10 min for 1 cycle. The PCR fragment was cloned 
into pCR4.0Topo vector and sequenced. The 5’ UTR sequence cloned by the TDT method 
was the exact the same as 5’ UTR obtained with RNA oligo-mediated 5’RACE method.   
 
5.3 Southern Blot with Non-radioactive DNA Probe for 3’ UTR Cloning  
During complete cDNA cloning, 3’ UTR cloning is the most challenging part. In fact, many 
novel gene cDNAs were published without 3’ UTR. The reason is that 3’ UTR cloning (by 3’ 
RACE) is based on the fact that every mRNA transcript has a polyA tail. By using polyT 
primer, mRNA transcript can be reverse transcribed into cDNA which then can be amplified 
by PCR for subsequence cloning. However, because polyT primer can anneal to any 
nucleotide fragment that contains a stretch of adenine, specificity of 3’RACE is usually poor 
which was demonstrated by multiple PCR bands in a DNA gel. However, by using gene 
specific DNA probe, a target band can be easily identified from a Southern blot. Once the 
target band was identified, the band can be removed from a fresh DNA gel and cloning can be 
followed. During 3’ UTR cloning of dar1 cDNA, many non-specific band were seen, thus it 
was necessary to develop the method to aid 3’ UTR cloning. Radioisotope labeled DNA probe 
was used in traditional Southern blot method but newer method uses non-radioactive DNA 
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probe. This section describes how to make non-radioactive probe by PCR method and how to 
use the probe to perform Southern blot experiment. The particular method described here was 
developed for making dar1 probe based on some published methods.   
 
The following procedure describes how to make PCR probe with DIG kit purchased from 
Roche Applied Sciences. The DIG Nonradioactive Nucleic Acid Labeling and Detection 
System (Roche Applied Sciences) were chosen to synthesize PCR probe. There are a few 
ways to incorporate DIG into a DNA probe. But PCR method was chosen because it can make 
highly sensitive DIG probes which can detect rare mRNA transcript. Specifically,15bT90-31 
plasmid (Reference chapter III) was used as PCR template which contains open reading frame 
of dar1 gene. PCR primers 5’-CTTTCGTCGATGTGCTCAAA-3’ (F-23, forward) and 5’-
TCCACGGGCTTTAAATGAAC-3’ (R-177, reverse) and Platinum Taq High Fidelity 
(Invitrogen) was used in PCR labeling reaction: 69 pg of 15bT90-31 plasmid, 0.2 µM of each 
primer, 5 μl of dNTP mix (normal NTP: DIG dNTP = 1:1), 5 μl of 10 x Taq buffer, 1.5 µl 
MgCl2 (50 mM) and 0.75 μl of Taq enzyme and dH2O to 50 µl were reacted under the 
following thermal profile: 95 °C for 2 min for 1 cycle; 95 °C for 30 sec, 52 °C for 40 sec, 
72 °C for 30 sec for 39 cycles; 72 °C for 7 min. The probe (5 µl) was examined on 1 % 
agarose gel to make sure that the probe incorporated DIG which can change PCR migration 
time. The DIG containing PCR band will move slower than normal PCR band of the same 
nucleotide size. Under the PCR reaction condition above, DIG probe was successfully made, 
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demonstrated by slightly higher molecular weight of DIG PCR band than non-DIG PCR band 
in agarose gel. The probe was frozen at -20 °C without any purification until hybridization.   
 
Before Southern transfer, 3’ RACE PCR reaction (10 µl) was resolved on 1 % agarose gel 
with DIG labeled molecular marker. The gel was stained with coomassie blue and a picture 
was taken. The gel was then treated with 0.2N HCl for 15 min with gentle shaking, rinsed 
twice with dH2O, denatured with Denaturation Buffer (0.5 M NaOH/1 M NaCl) for 2 x 30 
min, rinsed with dH20, soaked in 2 x 30 min in Neutralization Buffer, rinsed with dH20 and 
then ready for Southern transfer.  
 
The gel was transferred to positive charged nylon transfer membrane (GE Water & Process 
Technologies) by capillary method. To set up transfer assembly, soak the membrane in a 
crystal tray filled with 1 liter of Transfer Buffer (20 x SSC) with a gel cassette sitting in the 
buffer upside down and overlaid with a piece of 3 MM filter paper about the cassette width 
(i.d.) and with two sides overhanging in the buffer. On the top of the filter paper, DNA gel 
treated above was laid down and then the nylon member slightly smaller than gel (wetted in 
H2O first) was laid down and then 3 pieces of 3 MM filter paper, then 6 pieces of thick filter 
paper, then 4 cm thick of paper towel, then a plastic plate was put on the top of the assembly, 
and finally a 250 ml glass bottle weighing 300-400 grams was put on the top of the plastic 
plate. The DNA band in the gel were allowed to slowly transferred to the nylon membrane 
through capillary force overnight for 16 h in 20 x SSC. After transfer was done, the nylon 
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membrane was removed from the assembly with forceps and put on a piece of Saran Wrap 
with DNA side (or the side that face the gel during transfer) up and then the DNA was cross-
linked to the membrane by UV light for 2 x 15 sec with Strategene auto Cross-linker. The 
membrane now is ready for hybridization described below. 
 
DNA hybridization was performed by following steps: membrane was put into a hybridization 
tube with 10 ml Prehybridization Buffer (6xSSC, Denhardt’s solution, denatured Salmon 
Sperm DNA, formamide, EDTA, SDS) and incubated for 3-4 h at 42 °C oven with rotating 
balanced tubes. At the end of the prehybridization, add 20 µl denatured PCR DIG probe and 
allowed hybridization between DNA and the probe for overnight.  
 
Post-hybridization wash and band detection were described below. The membrane was 
removed from hybridization tube and washed with 2 x 100 ml x 20 min with the following 
buffer: 2X SSC/0.1 % SDS and then 0.2X SSC/0.1 % SDS. The membrane was then washed 
with 100 ml of Washing Buffer (Maleic Acid, NaCl, pH 7.5) twice at RT for 2 min with 
gentle shaking and then incubated with 100 ml 1 x blocking buffer (2.5 % BSA or 5 % dry 
milk in 1 x Maleic Buffer) for 1 h and then incubated with anti DIG antibody at 1: 10,000 
dilution for 30 min. The membrane was washed 2 x 100 ml with Washing Buffer and then 
equilibrated with Detection Buffer for 3 min, then with 1 ml CDP-Star for 5 min in a sheet 
protector followed by exposure to X-ray film for 15 min, then 5 min, then 1 min (3 films). 
The films were developed in a dark room. The molecular marker and probe control lit up and 
    122 
 
only two PCR bands were lit up. Remove the bands from a fresh DNA gel and perform 
cloning and sequencing. However, before the Southern method was worked out, dar1 3’ UTR 
was successfully cloned thus the method was not used. The successful 3’ RACE for dar1 
cloning was described in chapter III.  
 
5. 4 Mouse Kidney D-aspartate Oxidase Cloning, Expression and Application  
An alternative method to analyze D-aspartate racemase reaction results is to use a color assay, 
quite distinct from the CE-LIF assay described previously. The color assay can be achieved 
by using D-aspartate oxidase (DAO). The enzyme can degrade D-Asp to oxaloacetate, 
ammonia and hydrogen peroxide in the presence of flavin adenine dinucleotide (FAD), a 
redox cofactor.  Oxaloacetate is α-keto acid which can react with 2, 4-dinitrophenylhydrazine 
(DNPHe) to form a brown colored complex 2,4-dinitrophenylhydrazone (DNPHn) in the presence of 
NaOH.  The DNPHn can absorb light at 445 nm and the absorbance has linear relationship with D-Asp 
concentration within the range of 0-1.5 mM. The color assay has a few advantages compared to CE-
LIF.  For most, as many as 96 samples can be assayed simultaneously versus one sample a time with 
CE-LIF.  The assay is compatible with TCA (enzyme assay stopper reagent) which has to be removed 
for CE-LIF. No amino acid derivatization is required which is essential for CE-LIF analysis. The color 
assay also allows various controls to run simultaneously. The goal of the project is to clone DAO from 
mouse kidney and make DAO reagent for D-Asp assay.   
 
DAO was cloned by RT-PCR technique, expressed in E. coli and purified with NiNTA affinity resion 
as described below. DAO gene specific PCR cloning primers were designed based on the published 
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cDNA sequence by Katane (1). To clone the cDNA mouse kidney cortex was quickly dissected 
from a sacrificed animal. The tissue was quickly homogenized in 2 ml TRIzol (Invitrogen) 
reagent with motor-driven TissueRuptor (QIAGEN) homogenizer and total RNA was 
extracted from the homogenate by following TRIzol product instructions. Open reading frame 
(ORF) cloning was performed by RT-PCR method described as follows. Total RNA (1 μg) 
using Superscript III reverse transcriptase (Invitrogen) to make first strand cDNA with oligo 
dT primer following enzyme instruction. The first strad cDNA was then amplifed by PCR 
using the following primers: 5’-GGCATATGGACACAGTGTGTATTGCGGT-3’ (forward 
NdeI site underlined) and 5’-CCGGATCCCTACAGCTTCGACAAGGAAGC -3’ (reverse, 
Bam HI site underlined), and Platinum pfx DAN polymerase (Invitrogen) under the following 
thermo profile: 94 °C for 5min for 1 cycle; 94 °C for 15 sec, 55 °C for 30 sec and 68 °C for 
80 sec for 29 cycles; 68 °C for 10 min. Target PCR fragment of about 1000 bp was removed 
and isolated from agarose gel with QIAGEN kit, ligated to pCR2.1®-TOPO® vector and 
transformed into TOP 10 chemical competent cells (Invitrogen). Ten blue/light blue colonies 
were picked from X-gal plate, grown up and plasmids were sequenced. The desired clone was 
grown up and plasmid isolated and digested with NdeI and Bam HI and ligated to bacterial 
protein expression vector pET15b and transformed into TOP10 cells. After sequence was 
confirmed, target clone plasmid was transformed into BL21(DE3) cells. The protein 
expression was performed by growing a 3 ml overnight bacterial starter culture in 250 ml LB 
at 30 °C until O.D. 600 equals 0.5. Protein expression was then started by adding 0.01 mM 
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IPTG to the culture and induced for 20 h at 30 °C. Recombinant muDAO was purified from 
bacterial lysate with NiNTA resin by following Chapter III DAR1 purification methods.  
 
DAO activity was assayed by following the protocol as described by Katane et al.(1) with 
some modifications. To perform the enzyme assay, 40 mM D-aspartate substrate was 
incubated with 67 μM of FAD in 40 mM sodium phosphate buffer, pH 8.0 with 1 µg of 
purified enzyme in a total of 150 µl of reaction at 37 °C for 15 min. The reaction was then 
terminated by adding 5 % TCA followed by enzyme removal with centrifugation at 20, 000 x 
g for 10 min at 4 °C. The color assay was performed by adding 100 µl of 0.1 % 2, 4-
dinitrophenylhadrozine in 2 N HCl and incubated at 37 °C for 15 min and then incubated with 
750 µl of 3.75 M NaOH for 15 min followed by centrifugation at 8700 x g. The supernatants 
were read at O.D. 445 nm. The control samples had no amino acid substrate.  
    
The protein was expressed in E. coli under 0.01 mM IPTG induction only and about 300 μg of 
purified protein was obtained from 250 ml bacterial liquid culture, no DAO was expressed 
without IPTG. The enzyme can oxidize D-Asp but not D-Ser. It also showed a weak activity 
to D-Glu. However, unlike pig kidney DAO which has a strong activity towards D-Glu. The 
mouse enzyme can be used to set up a quick assay for D-Asp production by racemase but 
sensitivity was not as good as CE-LIF. For DAR1 assay especially kinetics assay, very small 
amount of D-Asp was converted which can’t be detected by DAO color assay. Thus the 
mouse DAO can be used for D-Asp racemase assay that is not quantitative.  
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 5.5 Generation of Monoclonal Antibody against D-amino acid-containing Peptides 
Like free D-amino acids, D-amino acid-containing peptides (DAACP) were thought to be 
only present in bacteria cell walls and antibiotics but not in higher organisms until after 1980 
when some biological active DAACPs were found in frog skin (2), snail ganglion (3), snail 
venom (4), Achitina fulica and Aplysia californica ganglion (5) and Octopus brain (6), and 
Spider Venom (7). These peptides share a common feature of having a D-amino acid in the 
second position from the N-terminus with a few exceptions; the D-amino acids in the peptides 
can vary but include almost every category of amino acids - small, polar, charged and 
aromatic amino acids (8). The D isoform residues in these peptides confer their biological 
activities since the replacement of D-form with L-form amino acids diminish or abolish 
observed activities (9).  Biological functions of these peptides are ranging from antimicrobial 
to cardioexcitatory to neuromodulation to hormonal functions. The DAACP biosynthesis is 
not very clear. But it could be from posttranslational modification (PTM) of L-amino acid 
configuration or incorporation of free-D-amino acid into a growing peptide during a 
ribosomal dependent or ribosomal independent biosynthesis process. But in eukaryotic 
system, predominant evidences have supported the conversion of L-amino acid residue to D-
amino acid residue by isomerase after a peptide is translated (9, 10). So far two isomerases 
responsible for DAACPs biosynthesis have been obtained from spinder venom (11) and frog 
skin (12). And most interestingly, an isomerase activity specifically in mouse heart tissue has 
been detected (13). The excitement of the field comes from the fact that most potent 
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cardioexcitatory peptides were found as DAACPs. For example, NdWFa (a D-amino acid was 
signified by a ‘d’ before a one code letter;  ‘a’ at the end means C-terminus is amide) was 
found in several species of snails and shown potent cardioexcitatory activity based on 
pharmacological assay (14, 15). Because of their wide range and important biological 
functions, finding and studying D-amino acid-containing peptides are obviously important.  
The current approaches of identification and quantification of such peptides include analytical 
method such as HPLC (16), CE chiral separations (17), mass spectrometry (8), NMR (18), 
and biological methods such as ELISA (19), IHC (20), and enzymatic cleavage (21). 
Immunohistochemistry using antibody can offer a unique advantage over the other methods in 
that it can provide DAACPs spatial distributions at cellular and subcellular levels as a way to 
study their functions. But by the time when the project was started, there was no any 
monoclonal antibody (mAb) against DAACPs. Polyclonal antibody contains anti carrier 
protein antibodies besides anti DAACP specificity thus can produce ambiguous experimental 
results or high background staining for IHC experiments; but a mAb is of single specificity 
against a DAACP antigen and can be produced from an immortal hybridoma cell line thus 
have unlimited source. It is even better if a “class-specific” monoclonal antibody can be 
made. Such antibody can bind to any short peptides of 3-5 amino acids that contain D-amino 
acids at the second position from N-terminus. If it can be made, the class specific antibody 
would recognize D-amino acid backbone but not side-chain functional group of a D-amino 
acid in a peptide thus it allows the detection of any DAACPs in a tissue or cells by IHC 
method. The basic method to make a monoclonal antibody is to use animal immunization 
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followed by hybridoma fusion and screening of hybridoma. But to make the class specific 
monoclonal antibody, a special immunization strategy was used. That is to force immune 
system to select D-amino acid backbone by repeatedly exposing animals with the structure. 
Specifically, mice were immunized with three different groups of peptides, immunized with 
one group a time, once every three weeks until all three groups are immunized. Each group 
contains three different peptides and every peptide has a different D-amino acid at the second 
position at N-terminus. Such spatial structure specific mAb might be found from hundreds of 
thousands of hybridoma clones that recognize other parts of the antigens injected by extensive 
hybridoma screening with ELISA.  An ELISA plate was coated with 9 different peptides. A 
screening hit should be able to recognize 9 peptides containing D-amino acids but not the 
control peptide set that contained only L-amino acids.     
 
The following peptide antigens were used to immunize animals. Group I peptides were: 
YdAEFLCa, FdTEFLCa and GdFFDCa ; group II peptides were: NdWfa, AdLAAc and 
AdMAAc; group III peptides were: AdLAACa, AdRAACa and AdDAACa. In each group, 
three peptides were mixed at equal molar ratios before chemically linking them to carrier 
protein KLH which helps to stimulate immune response. Test peptides for ELISA include 
AdAAAa, AdAACa, VdVVCa, and VdVVa. The “a” signify amide and ‘c’ signify carboxylic 
acid.  Group I and group III peptides are each conjugated to keyhole limpet hemocyanin 
(KLH) carrier protein (Calbiochem) using sulfo-SMCC (Pierce) cross-linker reagent by 
incubating 5-10 mg of carrier protein (KLH or BSA) with 2 mg of sulfo-SMCC in 0.1 M 
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NaPO4 buffer, pH 7.2, containing 0.15 mM NaCl at RT for 1 h with gentle mixing. The 
activated KLH was purified through a home-made G-25 sephadex column and then mixed 
with 1 mg of a peptide to be conjugated and allowed to react at RT for 2 h with gentle stirring. 
The group II peptides were conjugated to KLH, individually, using cross-linker reagent 1-
Ethyl-3-(3-dimethylaminopropyl)-carbodiimide (EDC) following the protocol by Hermanson 
(22). The different conjugation chemistries were chosen to avoid the same linker region 
between peptides and carrier protein KLH that are existed in all three groups thus might 
dominant immune response. The testing peptides were conjugated to BSA through either 
SMCC or EDC method. All conjugates were made at 1 mg/ml concentration based on carrier 
protein KLH or BSA quantity used.  
 
The first step to the desired monoclonal antibody is to immunize animals (5 female Balb/c 
mice) with the three peptide groups which all contain D-amino acid backbones by i.p. 
injection. Group I conjugates were used for the primary immunization; group II for the 
secondary immunization and group III for the tertiary immunization. The adjuvant is to help 
antigen to stay in the injection sites so that immune cells can encounter them and to enhance 
immune response to immune cells. Thus the peptides were mixed with an oil based adjuvant 
to form semi-solid emulsion for immunization. An equal volume of antigen (containing 50- 
100 µg of antigen) and adjuvant was mixed and emulsified by sonication. A potent adjuvant 
was needed for primary immunization to prime animal immune systems, in this case, 
complete Freund’s adjuvant was used to make antigen emulsion; and less potent incomplete 
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Freund’s adjuvant (with less side-effect to animal) was used for the subsequent 
immunizations. The total antigen dosage was 50 µg in 100 µl antigen emulsion for one mouse 
(Balb/c mice, 8-10 weeks old when the first immunization was started).  The second 
immunization was performed three weeks after the primary immunization and the tertiary 
immunization 3 weeks after the second one. One week from the third immunization, small 
quantity of blood was taken from each mouse by leg vein bleeding and each serum was tested 
against testing peptides in ELISA assay to see if the animals responded to the injected 
peptides.  
 
The serum test results indicated that all five animals responded peptide antigens very well. 
Two best responders were sacrificed to make hybridoma cell lines. Each cell line can secret a 
particular monoclonal antibody.  The hybridoma cell lines were made by hybridoma 
technology described by Kohler et al. (23).  To make hybridoma cell lines, a mouse (best 
immune responder) was sacrificed and the spleenocytes were isolated and fused with mouse 
myeloma cells with polyethylene glycol to produce fusion clones. About 200 fusion clones 
were grown up and their culture medium (containing monoclonal antibody) were screened 
against testing peptides in ELISA assay. The best clones with highest specific ELISA signal 
against DAACP were then tested against LAACP of the same peptide sequence.   
 
Unfortunately, all positive clones that recognized DAACP also recognized its LAACP 
counterpart, meaning that the monoclonal antibodies were not specific to D-amino acid 
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backbone. The reason is likely due to that fact that peptide residue side chain functional 
groups have more chance to contact with immune cells than peptide backbones thus can 
stimulate immune systems. Since the side chain functional groups are the same in both 
DAACP and LAACP, immune system can’t distinguish them thus the monoclonal antibodies 
were not specific to either peptide groups. Maybe the D-backbone specific antibody was there 
but it is certainly rare and requires an extensive screening to find it which means more time 
and cost would be involved. After considering the next steps it was decided that other 
approaches could be used to characterize DAACPs thus the project was dropped.   
 
5.6 Microdialysis Fluid Analysis for L-Glutamate Change with CE-LIF 
The goal of the project is to examine if L-glutamate injection at pedunculopontine tegmental 
nucleus (PPTg) at brainstem can stimulate L-glutamate change in rat hypothalamus 
Suprachiasmatic nucleus (SCN) at circadian clock 15 (or three hours after lights are turned 
off).  The SCN is a part of the hypothalamus and controls circadian rhythms. This is a 
collaboration project with Dr. Martha Gillette’s lab. My part of job was to analyze 72 
microdialysis samples with CE-LIF and provide semi-quantitative data of L-Glu from each 
sample which was presented as L-Glu peak area normalized with CE-LIF internal control 
normalized L-cysteic acid peak.  
 
SCN fluid samples are described in detail below. Nine mice received microdialysis device 
implants at hypothalamus SCN region. The mice were divided into three groups: A, B and C, 
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each group had three animals and received three different treatments at PPTg. From each 
group, microdialysis fluids from SCN were collected at 9 different time points. First, three 
baseline samples (before L-glutamate injection) were collected one hour before PPTg 
treatment with 20 min apart for each collection. The baseline samples were designated as B1, 
B2 and B3. At circadian clock 15 Group A received artificial cerebral spinal fluid; Group B 
received L-Glu (30 ng/nl) and Group C received three times higher concentration of L-Glu or 
90 ng/nl by syringe injection at brainstem PPTg. SCN fluid samples were collected from each 
mouse at the time of injection and the samples were designated as INJ. Ten minutes after the 
injections, the first post-injection SCN fluid samples were collected from all animals, and then 
20 min after injection and then 40 min and 60 min after injections. Thus there were 4 groups 
of post-injection samples that were designated as PS1, PS2, PS3 and PS4. In total, there are 
27 baseline samples, 9 injection samples, 36 post-injection samples or 72 samples. Aliquots of 
15 µl SCN fluid from each sample was received from Martha Gillette Lab. The fluid samples 
were frozen at -80 ˚C immediately upon receiving until analyzed by CE-LIF.  
 
The CE-LIF analysis of SCN fluid samples are described below. The samples were thawed 
and analyzed one a time. A fluid sample was slowly thawed on ice and 3 µl was removed 
from the stock (remaining put back to -80 °C immediately) and derivatized with 1 µl of 200 
µM of L-cysteic acid (L-CA) in H2O, 3 µl of 2 mM of NDA in methanol and 3 µl of 20 mM 
KCN in 50 mM borate buffer, pH 9.4 at RT for 1 h. The sample was then diluted 1:1 with 
separation buffer containing 50 mM SDS, 20 mM ß-cyclodextrin, 23 % methanol in 50 mM 
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borate buffer, pH 9.4. Derivatized sample was injected into CE capillary (50 µm inner 
diameter, 360 µm outer diameter) at 7 kV for 4 sec and separated under 20 kV for 45-60 min.  
Between two samples, the capillary was cleaned with 3 M NaOH for 5 min, rinsed with 
deionized water for 5 min and then equilibrated with the separation buffer until baseline was 
stabilized. The fluorescence counts of versus analyte retention time were plotted 
(automatically by the instrument software) to give rise to CE-electrophoregram. L-Glu, L-Asp 
and L-cysteic acid peaks were identified by standard amino acid spikes. L-Glu and L-Asp 
peaks were calculated by Origin8 integration function and the values were normalized with 
internal control L-CA peak area. The normalized analyte peak areas from three repeating 
mouse samples were averaged and presented in the figures.    
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The CE-LIF analysis results are shown in Figure 5.1 and Figure 5.2.  Two representative CE-
electrophoregrams from two sample runs were shown in Fig. 5.1 and normalized L-Glu and 
L-Asp values were shown in Figure 5.2. It is very interesting that L-Glu baseline samples 
showed more difference between animals than L-Asp baselines between the same animals, 
and in addition, the group of animals with high L-Glu baselines had lower L-Asp baselines 
and verse visa. During INJ, however, L-Glu was increased in all three groups but L-Asp was 
decrease in all three groups. After injection, L-Glu fell down quickly to the baseline level 
after twenty minutes but L-Asp continued to drop over 40 minutes of time and all the sudden 
showed a big increase after 60 min post-injection. Finally, the two dosages of L-Glu injection  
 
 
with three times difference in L-Glu concentrations did not make any difference in SCN L-
Glu and L-Asp response levels. Those data were used to plan following L-Glu experiments 
that are still undergoing.  
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5.7 Figures 
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Fig.  5.1  CE‐electrophoregram  of  mouse  SCN  microdialysis  fluid.  The  experimental  set  up  was 
described in section 5.5.  Microdialysis fluid sample was collected from mouse #1 before L‐glutamate 
injection to PPTg neurons  (A). Microdialysis fluid sample was collected from mouse # 1 40 minutes 
after L‐Glu injection to PPTg neurons (B). The peaks pointed by the left arrow are L‐glutamate; by the 
middle arrow are L‐Asp peaks and by the right arrow are L‐cysteic acid.  
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Fig. 5.2 Mouse SNC microdialysis fluid L‐Glu and L‐Asp content analysis by CE‐LIF. L‐Glu analysis data 
(A); L‐Asp analysis data (B). B1‐B3 are baseline samples collected before PPTg stimuation with L‐
glutamate, INJ samples were collected at injection time, PS1‐PS4 samples were collected 10 min, 20 
min, 40 min and 60 min after the injection  time.  Each bar represents average relative fluorescence 
counts adjusted by internal control from three mice received the same treatment. Series 1 were 
Group A samples, series 2 were Group B samples and series 3 were Group C samples. The treatment 
of each group was described in the text in section 5.5.  
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